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EIS INHIBITORS

Furthermore, Eis homologues from Mycobacterium smegmatis, Mycobacterium abscessus, Anabaena variabilis,
Bacillus anthracis, Gordonia bronchialis, Kocuria rhizophila (9), and Tsukamurella paurometabola are also functional AACs, which exhibit differences in regiospecificity
and can be inhibited by chlorhexidine, a non-clinically
relevant Eis Mtb inhibitor. In addition to AG substrate
versatility, E~ enzymes display some acyl-CoAco-substrate
promiscuity and can acetylate non-AG molecules containing
lysine residues, such as capreomycin and the JNK-specific
dual-specificity protein phosphatase 16 (DUSP16)/mitogenactivated protein kinase phosphatase-7 (MKP-7) pair. These
observations underscore the uniqueness and versatility of
Eis AG modifying activity and its high capacity for inactivation of diverse AG drugs.
The development of AGs that cannot be modified by Eis
or a novel therapy that would involve an Eis inhibitor used
in combination with KAN are two possible approaches to
resolve the need in the field of drug resistant tuberculosis.
The former route is complicated by the ability of Eis to
accept structurally diverse AGs as substrates, whereas the
latter route is potentially more suitable. The latter approach
to combat drug resistance arising as a result of drugmodifying enzymes, then, is to use a combination therapy
that includes an antibiotic along with an inhibitor of its
associated resistance enzyme. In Mtb, including MDR TB,
the combination of the ~-lactamase inhibitor clavulanate and
the ~-lactam meropenem was demonstrated to overcome
resistance to ~-lactam antibiotics. With this strategy in mind,
efforts have also been made towards identifying inhibitors of
aminoglycoside acetyltransferases (AACs) present in nonmycobacteria, with limited pre-clinical progress, but these
are not applicable for the mechanistically and structurally
distinct Mtb Eis acetyltransferase. For example, aminoglycoside-acetyl coenzyme A bi-substrate inhibitors were found
to potently inhibit AAC(6') enzymes in vitro, but were not
effective in cell-based assays. Numerous cationic peptides
that inhibit AAC(6') enzymes in vitro were identified, but
these also displayed no antibacterial effects against resistant
bacterial strains due to membrane permeability issues.
Finally, the natural product aranorosin was found to be an
inhibitor of the bifunctional AAC(6')-Ie/APH(2")-Ia
enzyme, and its combination with the aminogly_c~si_de
arbekacin was shown to stop the growth of a methic1llmresistant Staphylococcus aureus strain.
We previously reported that some Eis inhibitors displayed
AG-competitive and mixed modes of action, establishing a
proof of principle for inhibition of Eis in vitro.
A two-drug combination therapy where one drug targets
an offending cell and the other targets a resistance mechanism to the first drug is a time-tested, yet underexploited
approach to combat or prevent drug resistance in an infectious disease. Furthermore, there remains a need for
approaches to combat drug resistant TB.

RELATED APPLICATIONS
This application claims priority from U.S. Provisional
Application Ser. Nos. 62/595,947 filed Dec. 7, 2017, and
62/431,744 filed Dec. 8, 2016, the entire disclosures of
which are incorporated herein by this reference.
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This invention was made with govermnent support under
National Institutes of Health (NIH) Grant AI090048. The
govermnent has certain rights in the invention.
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TECHNICAL FIELD
The presently-disclosed subject matter relates to compositions useful as inhibitors of acetyltransferase Eis, a mediator ofkanamycin resistance in Mycobacterium tuberculosis,
and their methods of use. In particular, the compositions are
sulfonamide-based and sulfonyl isothiazole-based small
molecules.

20

INTRODUCTION
25

A major cause of tuberculosis (TB) resistance to the
aminoglycoside kanamycin (KAN) is the Mycobacterium
tuberculosis (Mtb) acetyltransferase Eis. Eis is a superacetyltransferase from M. tuberculosis that inactivates all
clinically used aminoglycosides. Upregulation of Eis is a
frequent cause of clinical resistance to the aminoglycoside
kanamycin (KAN) in TB. Upregulation of this enzyme is
responsible for inactivation of KAN through acetylation of
its amino groups.
Tuberculosis (TB) is an infectious disease caused by
Mycobacterium tuberculosis (Mtb ), and a major global
health threat. In 2013, approximately 9.0 million people
developed TB, and nearly 1.5 million died from the disease.
Due to the spread of multidrug-resistant TB (MDR TB),
defined as TB with resistance to at least isoniazid and
rifampin (-10% of new TB cases in 2013) and extensively
drug-resistant TB (XDR TB), defined as MDR TB with
added resistance to at least a fluoroquinolone and an injectable drug (i.e., kanamycin (KAN), capreomycin, or amikacin), the need for novel strategies to combat drug resistant
TB is urgent.
The aminoglycosides (AGs) kanamycin A (KAN) and
amikacin (AMK) are used to treat MDR- and XDR-TB, but
resistance to these agents occurs as well. Among mechanisms of clinically important transmissible drug resistance is
the recently identified inactivation of an MDR-TB therapeutic, the aminoglycoside kanamycin, through its acetylation
by an upregulated acety ltransferase, the Eis (enhanced intracellular survival) enzyme. We previously demonstrated that
the Mtb Eis protein (Eis_Mtb) is an acetyltransferase
capable of multiacetylating a variety of AGs, including the
TB therapeutics KAN and AMK, via a random sequential
mechanism, thereby abolishing the antibiotic activity of
these drugs. The ability of acetylating an AG molecule at
multiple amine positions due to its unique structure distinguishes Eis from other AG acetyltransferases (AACs),
which are known to be exquisitely regiospecific. A crystal
structure of Eis_Mtb in complex with coenzyme A and
tobramycin demonstrated how tobramycin could interact
with the Eis active site in two binding modes for the
observed diacetylation of the 6'- and 3"-amines of this AG.
Multiacetylation by Eis has a defined pattern for each AG:
the number of acetylations and the positions of the amino
groups that get acetylated depend on the structure of the AG.

30
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The presently-disclosed subject matter meets some or all
of the above-identified needs, as will become evident to
those of ordinary skill in the art after a study of information
provided in this document.
This S=ary describes several embodiments of the
presently-disclosed subject matter, and in many cases lists
variations and permutations of these embodiments. This
Summary is merely exemplary of the numerous and varied
embodiments. Mention of one or more representative
features of a given embodiment is likewise exemplary. Such
an embodiment can typically exist with or without the
feature(s) mentioned; likewise, those features can be applied

US 10,253,035 B2
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to other embodiments of the presently-disclosed subject
matter, whether listed in this Summary or not. To avoid
excessive repetition, this Summary does not list or suggest
all possible combinations of such features.
The presently-disclosed subject matter includes compounds, compositions, and methods involving inhibition of
Eis. In some embodiments, the compound has a scaffolds
selected from the following:

5

The presently-disclosed subject matter also includes a
pharmaceutical composition comprising a compound as
described herein, and a suitable pharmaceutical carrier.
In some embodiments, the composition includes a compound as described herein and an aminoglycoside. In some
embodiments, the aminoglycoside is kanamycin (KAN).
15
The presently-disclosed subject matter also includes a
method of inhibiting Eis, which involves administering an
effective amount of a compound or composition as described
herein. In some embodiments, the method further involves
administering an aminoglycoside. In some embodiments,
20 the aminoglycoside is kanamycin (KAN).
The presently-disclosed subject matter also includes a
method of treating aminoglycoside-resistant Mycobacterium
tuberculosis (Mtb ), which involves administering an effective amount of a compound or composition as described
25 herein. In some embodiments, the method also involves
administering an aminoglycoside. In some embodiments,
the aminoglycoside is kanamycin (KAN). In some embodiments, the aminoglycoside is administered to a subject in
need of treatment for aminoglycoside-resistant Mtb.
30
The presently-disclosed subject matter also includes a kit,
which can include a compound or composition as described
herein, packaged together with an aminoglycoside.
10
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The novel features of the invention are set forth with
particularity in the appended claims. A better understanding
of the features and advantages of the present invention will
be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the
principles of the invention are used, and the accompanying
drawings of which:
FIG. 1 includes preparation schemes and structures of
exemplary Eis inhibitor scaffolds according to the presentlydisclosed subject matter and discussed in Example 1.
FIG. 2 includes structures of exemplary compounds
according to the scaffolds set forth in FIG. 1.
FIG. 3 includes structures of additional exemplary compounds according to the scaffolds set forth in FIG. 1.
FIG. 4 includes five panels, including models of compound 2g (panels A and B) and la (panels C and D) in
complex with a monomer of Eis_Mtb (panels A and C) or in
complex with Eis (panels B and D), and the structures of
compounds A and B (panel E) that were used to model
compounds 2g and la in the active site of Eis.
FIG. 5 includes representative IC 50 curves for exemplary
compounds according to the scaffolds set forth in FIG. 1.
FIG. 6 includes preparation schemes and structures of
exemplary Eis inhibitor scaffolds according to the presentlydisclosed subject matter and discussed in Example 2.
FIG. 7 includes results of mammalian cytotoxicity studies
of selected compounds (le*, li*, 2c*, 2h*, and 2i*) alone
(represented as dark color columns) or in the presence of 50
µg/mL (equivalent to 86 µM) KAN (represented as light
color colunms immediately to the right of the dark color
colurmi of the corresponding compound in the absence of
KAN) against A. A549, B. HEK-293, and C. J774A.1 cells.
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FIG. 8 illustrates the inhibitor/aminoglycoside binding
site showing the superimposition of Eis inhibitors and TOB
from several crystal structures. The chemical structures of
inhibitors 2k*, 13g, and 39, as well as of TOB are shown
below the crystal structure.
FIG. 9 includes results of a study showing cytotoxicity of
KAN againstA549, HEK-293, and J774A.1 mammalian cell
lines.
FIG. 10 includes a crystal structure of EisC204A-CoAinhibitor 2k* complex (PDB ID 5TVJ) (panel A), and a
zoom-in view of the binding pocket of compound 2k* (panel
B).
FIG. 11 includes representative IC 50 curves for exemplary
compounds according to the scaffolds set forth in FIG. 6.
FIG. 12 includes preparation schemes and structures of
exemplary Eis inhibitor scaffolds according to the presentlydisclosed subject matter and discussed in Example 3.
FIG. 13 includes a cartoon view of the crystal structure of
Eis in complex with compound 39 and CoA, including the
overall view of a monomer ofEis-CoA-inhibitor 39 complex
(panel A), the zoomed-in view of the AG-binding site with
the bound inhibitor (panel B), and a schematic of Eisinhibitor 39 contacts (panel C).
FIG. 14 includes the crystal structure of Eis in complex
with inhibitor 39 from this study and a previously published
Eis inhibitor (labeled 13g in ref2 ) with an isothiazole S,Sdioxide heterocyclic core obtained by superimposition of the
crystal structures (panel A), and the zoomed-in view of the
binding site with the bound inhibitors and TOB (panel B).
FIG. 15 includes representative IC 50 curves for exemplary
compounds according to the scaffolds set forth in FIG. 12.
FIG. 16 includes a schematic representation of the winnowing of small organic molecules to 18 showing inhibition
of both Eis enzymatic activity and growth of Mtb K204 in
the presence of KAN (panel a), and structures of exemplary
Eis inhibitor scaffolds according to the presently-disclosed
subject matter and discussed in Example 4.
FIG. 17 includes further structures of Eis inhibitor according to the presently-disclosed subject matter and discussed
in Example 4.
FIG. 18 includes crystal structures ofEisC204A from Mtb
in complex with 13g (a and b) and Ile (d and e), and the
overall views of the Eis monomer with the inhibitors bound
(a and c) and zoom-in views of the active site (band e) show
that the inhibitors occupy a site overlapping with the aminoglycoside substrate-binding site; superposition of these
respective inhibitor structures with the previously reported
crystal structure of EisC204A in complex with CoA and
tobramycin is shown in panels c and f.
FIG. 19 includes representative IC 50 curves for exemplary
compounds according to the scaffolds set forth in FIGS. 16
and 17.
FIG. 20 includes a structural comparison of inhibitor 13g
(panel a) and TOB bound in the active site of EisC204A
(panel b ).
FIG. 21 includes representative IC 50 curves for exemplary
compounds described in Example 5.
FIG. 22 includes results of a study showing cytotoxicity
of KAN against A549, HEK-293, and J774A.1 mammalian
cell lines for exemplary compounds described in Example 5.

and other embodiments, will be evident to those of ordinary
skill in the art after a study of the information provided in
this document. The information provided in this document,
and particularly the specific details of the described exemplary embodiments, is provided primarily for clearness of
understanding and no unnecessary limitations are to be
understood therefrom. In case of conflict, the specification of
this document, including definitions, will control.
The presently-disclosed subject matter is illustrated by
specific but non-limiting examples throughout this description. The examples may include compilations of data that are
representative of data gathered at various times during the
course of development and experimentation related to the
present invention(s). Each example is provided by way of
explanation of the present disclosure and is not a limitation
thereon. In fact, it will be apparent to those skilled in the art
that various modifications and variations can be made to the
teachings of the present disclosure without departing from
the scope of the disclosure. For instance, features illustrated
or described as part of one embodiment can be used with
another embodiment to yield a still further embodiment.
All references to singular characteristics or limitations of
the present disclosure shall include the corresponding plural
characteristic(s) or limitation(s) and vice versa, unless otherwise specified or clearly implied to the contrary by the
context in which the reference is made.
All combinations of method or process steps as used
herein can be performed in any order, unless otherwise
specified or clearly implied to the contrary by the context in
which the referenced combination is made.
The presently-disclosed subject matter includes compounds that are useful for inhibiting Eis.
In some embodiments, the compound is
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wherein R is selected from the group cons1stmg of Ph,
o-F-Ph, m-F-Ph, m-Cl-Ph, m-Br-Ph, m-OMe-Ph, p-F-Ph,
p-Cl-Ph, p-Br-Ph, p-Me-Ph, naphthyl, Et, t-Bu, and m-NO 2 Ph.
In some embodiments, the compound is
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DESCRIPTION OF EXEMPLARY
EMBODIMENTS
The details of one or more embodiments of the presentlydisclosed subject matter are set forth in this document.
Modifications to embodiments described in this document,
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wherein R 1 is selected from the group consisting of H, p-F,
m,p-di-F; and R 2 is selected from the group consisting ofH,
o-F, m-F, m-Cl, m-Br, m-OH, m-OMe, p-F, p-Cl, p-Br, and
p-Me.
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wherein
W is selected from the group consisting of H, CH 3 , F, Cl,
OCH 3 , and OCH 2 CH 3 ,
X is selected from the group consisting of H, Cl, Br,
OCH 3 , OCH 2 CH 3 , and OCH 2 O,
Y is selected from the group consisting of H, CH 3 ,
CH 2 CH 3 , Br, F, Cl, OCH 3 , OCH 2 CH 3 , O(CH)(CH 3 ) 2 ,
OCH 2 O, N(CH 3 ) 2 , N(CH 2 CH 3 ) 2 , and
Z is selected from the group consisting of H and OCH 3 ;
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CH 2 CH 3 , CH(CH 3 ) 2 , F, Cl, Br, OCH 3 , OCH 2 O, OCH 2 CH 3 ,
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wherein X is selected from the group consisting of: CH 3 ,
CH 2 CH 3 , (CH 2 ) 2 CH 3 , CH(CH 3 ) 2 , CH(CH 3 )CH 2 CH 3 ,
C(CH 3 ) 3 , (CH 2 ) 2 CH(CH 3 ) 2 , (CH 2 ) 2 OCH 3 , (CH 2 ) 3 OCH 3 ,
(CH 2 ) 3 OCH 2 CH 3 , (CH 2 ) 3 OCH(CH 3 ) 2 ,

W is selected from the group consisting of H, CH 3 , F, Cl,
CH 2 CH 3 , SCH 3 , OCH 3 , OCH 2 O, and CO 2 CH 3 ,
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Y is selected from the group consisting of H, CH 3 , F, Cl,
OCH 3 , CO 2 CH 3 , Br, CH 2 CH 3 , and OCH 2 CH 3 ,
Z is selected from the group consisting of H, CH 3 , and
CH 2 CH 3 ,
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wherein R is selected from the group consisting of 4-Cl, 4-F,
4-Br, 3-Cl, 3-F, and H; and Ar is selected from the group
consisting of Ph, 3-Py, 2-Py, 4-Py, and Ph.
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The presently-disclosed subject matter further includes
methods or inhibiting Eis and methods of treating aminoglycoside-resistant Mtb. In some embodiments the method
involves administering a compound or composition as disclosed herein. In some embodiments, the method involves
administering a compound or composition to a subject in
need of treatment for aminoglycoside-resistant Mtb. In some
embodiments, the method further includes administering an
aminoglycoside. In some embodiments the aminoglycoside
is kanamycin (KAN).
The presently-disclosed subject matter further includes
composition that include at least one compound disclosed
herein as an Eis inhibitor, and an aminoglycoside. In some
embodiments the aminoglycoside is kanamycin (KAN).
The presently-disclosed subject matter further includes
kits comprising at least one compound disclosed herein as an
Eis inhibitor, packaged together with an aminoglycoside. In
some embodiments the aminoglycoside is kanamycin
(KAN).
The presently disclosed subject matter includes identified
potent inhibitors of Eis enzymatic activity with resulting
sensitization of KAN-resistant Mtb cells, in which the
resistance to KAN is caused by Eis upregulation. The
inhibitors bind in the AG binding pocket blocking the access
of AGs to the active site of the enzyme. The inhibitor
binding is accompanied by induced-fit conformational
changes of the protein. These compounds have a great
potential for further development as KAN adjuvants in Mtb.
The presently-disclosed subject matter includes novel
small molecule compositions, and small molecule compositions useful as inhibitors of Eis enzymatic activity. In some
embodiments, the inhibitors can effectively overcome
kanamycin resistance in strains of Mtb.
The presently-disclosed subject matter further includes a
pharmaceutical composition including a small molecule, as
described herein, and a suitable pharmaceutical carrier. The
presently-disclosed subject matter also includes a method of
treating a bacterial infection comprising administering to an
individual an effective amount of a small molecule Eis
inhibitor, as disclosed herein. In some instances, the pharmaceutical composition is administered with an aminoglycoside. In some instances the aminoglycoside is Kanamycin.
Methods of treating kanamycin resistance are also disclosed herein, comprising administering a small molecule
composition disclosed herein. Also provided are methods of
treating tuberculosis comprising administering the Eis
inhibitors disclosed herein with kanamycin.
In some embodiments, a method is provided for treating
antibiotic resistance and/or inhibiting Eis enzymatic activity
in a cell. In some embodiment the method includes contacting the cell with compounds disclosed herein. The term
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"contacting" as used herein refers to any means by which the
compound is brought into sufficient proximity and/or in
direct contact with a cell such that the cell is capable of
receiving the compound. For instance, in some embodiments
contact refers to coating or otherwise exposing a cell to the
compound. In some embodiments contact refers to culturing
a cell in a solution that includes the compound. In other
embodiments the cell is within a subject, and contact refers
to administering a compound to the subject such that a cell
within the subject is capable of receiving the novel small
molecule compounds. In some embodiments, such methods
can include further administration of an antibiotic at the
same time as the administration of the compound, or prior to
or subsequent to the administration of compound. In some
embodiments, the antibiotic is kanamycin. The presentlydisclosed subject matter further includes composition that
include at least one compound disclosed herein as an Eis
inhibitor, and an aminoglycoside. In some embodiments the
aminoglycoside is kanamycin (KAN). In some embodiments, the cell exhibits resistance to kanamycin. In some
embodiments, said cell is within a subject diagnosed with
tuberculosis.
While the following terms used herein are believed to be
well understood by one of ordinary skill in the art, definitions are set forth to facilitate explanation of the presentlydisclosed subject matter.
The terms "polypeptide", "protein", and "peptide", which
are used interchangeably herein, refer to a polymer of the
protein amino acids, or amino acid analogs, regardless of its
size or function. Although "protein" is often used in reference to relatively large polypeptides, and "peptide" is often
used in reference to small polypeptides, usage of these terms
in the art overlaps and varies. The term "polypeptide" as
used herein refers to peptides, polypeptides, and proteins,
unless otherwise noted. The terms "protein", "polypeptide",
and "peptide" are used interchangeably herein when referring to a gene product. Thus, exemplary polypeptides
include gene products, naturally occurring proteins,
homologs, orthologs, paralogs, fragments and other equivalents, variants, and analogs of the foregoing.
Unless otherwise indicated, the term "administering" is
inclusive of all means known to those of ordinary skill in the
art for providing a preparation to a subject, including administration by inhalation, nasal administration, topical administration, intravaginal administration, ophthalmic administration,
intraaural
administration,
intracerebral
administration, intravitreous administration, intracameral
administration, posterior sub-Tenon administration, posterior juxtascleral administration, subretinal administration,
suprachoroidal administration, cell-based administration or
production, rectal administration, and parenteral administration, including injectable such as intravenous administration, intra-arterial administration, intramuscular administration, and/or subcutaneous administration. Administration
can be continuous or intermittent. A preparation can be
administered therapeutically; that is, administered to treat an
existing condition of interest. A preparation can be administered prophylactically; that is, administered for prevention
of a condition of interest.
In some embodiments a subject will be administered an
effective amount of at least one compound and/or composition provided in the present disclosure. In this respect, the
term "effective amount" refers to an amount that is sufficient
to achieve the desired result or to have an effect on an
undesired condition. For example, a "therapeutically effective amount" refers to an amount that is sufficient to achieve
the desired therapeutic result or to have an effect on unde-

sired symptoms, but is generally insufficient to cause
adverse side effects. The specific therapeutically effective
dose level for any particular patient will depend upon a
variety of factors including the disorder being treated and
the severity of the disorder; the specific composition
employed; the age, body weight, general health, sex and diet
of the patient; the time of administration; the route of
administration; the rate of excretion of the specific compound employed; the duration of the treatment; drugs used
in combination or coincidental with the specific compound
employed and like factors well known in the medical arts.
For example, it is well within the skill of the art to start doses
of a compound at levels lower than those required to achieve
the desired therapeutic effect and to gradually increase the
dosage until the desired effect is achieved. If desired, the
effective daily dose can be divided into multiple doses for
purposes of administration. Consequently, single dose compositions can contain such amounts or submultiples thereof
to make up the daily dose. The dosage can be adjusted by the
individual physician in the event of any contraindications.
Dosage can vary, and can be administered in one or more
dose administrations daily, for one or several days. Guidance
can be found in the literature for appropriate dosages for
given classes of pharmaceutical products. In further various
aspects, a preparation can be administered in a "prophylactically effective amount"; that is, an amount effective for
prevention of a disease or condition.
Additionally, the terms "subject" or "subject in need
thereof' refer to a target of administration, which optionally
displays symptoms related to a particular disease, pathological condition, disorder, or the like. The subject of the herein
disclosed methods can be a vertebrate, such as a manimal, a
fish, a bird, a reptile, or an amphibian. Thus, the subject of
the herein disclosed methods can be a human, non-human
primate, horse, pig, rabbit, dog, sheep, goat, cow, cat, guinea
pig or rodent. The term does not denote a particular age or
sex. Thus, adult and newborn subjects, as well as fetuses,
whether male or female, are intended to be covered. A
patient refers to a subject afflicted with a disease or disorder.
The term "subject" includes human and veterinary subjects.
In some embodiments the subject in need thereof will be
suffering or will have been diagnosed tuberculosis and/or
related diseases, disorders, pathologies, or conditions.
As used herein, the terms "treatment" or "treating" relate
to any treatment of a condition of interest, including but not
limited to prophylactic treatment and therapeutic treatment.
As such, the terms treatment or treating include, but are not
limited to: preventing a condition of interest or the development of a condition of interest; inhibiting the progression
of a condition of interest; arresting or preventing the development of a condition of interest; reducing the severity of a
condition of interest; ameliorating or relieving symptoms
associated with a condition of interest; and causing a regression of the condition of interest or one or more of the
symptoms associated with the condition of interest.
Unless defined otherwise, all technical and scientific
terms used herein have the same meaning as commonly
understood by one of ordinary skill in the art to which the
presently-disclosed subject matter belongs. Although any
methods, devices, and materials similar or equivalent to
those described herein can be used in the practice or testing
of the presently-disclosed subject matter, representative
methods, devices, and materials are now described.
Following long-standing patent law convention, the terms
"a", "an", and "the" refer to "one or more" when used in this
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application, including the claims. Thus, for example, reference to "an enzyme" includes a plurality of such enzymes,
and so forth.
Unless otherwise indicated, all numbers expressing quantities of ingredients, properties such as reaction conditions,
and so forth used in the specification and claims are to be
understood as being modified in all instances by the term
"about". Accordingly, unless indicated to the contrary, the
numerical parameters set forth in this specification and
claims are approximations that can vary depending upon the
desired properties sought to be obtained by the presentlydisclosed subject matter.
As used herein, the term "about," when referring to a
value or to an amount of mass, weight, time, volume,
concentration or percentage is meant to encompass variations of in some embodiments ±5%, in some embodiments
±1%, in some embodiments ±0.5%, in some embodiments
±0.1%, and in some embodiments ±0.01% from the specified amount, as such variations are appropriate to perform
the disclosed method.
As used herein, ranges can be expressed as from "about"
one particular value, and/or to "about" another particular
value. It is also understood that there are a number of values
disclosed herein, and that each value is also herein disclosed
as "about" that particular value in addition to the value itself.
For example, if the value "10" is disclosed, then "about 10"
is also disclosed. It is also understood that each unit between
two particular units are also disclosed. For example, if 10
and 15 are disclosed, then 11, 12, 13, and 14 are also
disclosed.
As will be recognized by one of ordinary skill in the art,
the terms "reduce", "reducer", "reduction", "reducing",
"suppression," "suppressing," "suppressor," "inhibition,"
"inhibiting" or "inhibitor" do not refer to a complete elimination of angiogenesis in all cases. Rather, the skilled artisan
will understand that the term "reducing", "suppressing" or
"inhibiting" refers to a reduction or decrease in a particular
condition. Such reduction or decrease can be determined
relative to a control. In some embodiments, the reduction or
decrease relative to a control can be about a 1, 2, 3, 4, 5, 6,
7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23,
24,25, 26,27,28, 29, 30,31,32, 33,34,35,36, 37,38,39,
40,41, 42,43,44, 45, 46,47,48, 49, 50, 51, 52, 53, 54, 55,
56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71,
72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87,
88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100%
decrease.
As described herein, the presently-disclosed subject matter further includes pharmaceutical compositions comprising at least one enzyme described herein together with a
pharmaceutically acceptable carrier.
The term "pharmaceutically acceptable carrier" refers to
sterile aqueous or nonaqueous solutions, dispersions, suspensions or emulsions, as well as sterile powders for reconstitution into sterile injectable solutions or dispersions just
prior to use. Proper fluidity can be maintained, for example,
by the use of coating materials such as lecithin, by the
maintenance of the required particle size in the case of
dispersions and by the use of surfactants. These compositions can also contain adjuvants such as preservatives,
wetting agents, emulsifying agents and dispersing agents.
Prevention of the action of microorganisms can be ensured
by the inclusion of various antibacterial and antifungal
agents such as paraben, chlorobutanol, phenol, sorbic acid
and the like. It can also be desirable to include isotonic
agents such as sugars, sodium chloride and the like. Prolonged absorption of the injectable pharmaceutical form can

be brought about by the inclusion of agents, such as aluminum monostearate and gelatin, which delay absorption.
Injectable depot forms are made by forming microencapsule
matrices of the drug in biodegradable polymers such as
polylactide-polyglycolide, poly(orthoesters) and poly(anhydrides). Depending upon the ratio of drug to polymer and the
nature of the particular polymer employed, the rate of drug
release can be controlled. Depot injectable formulations are
also prepared by entrapping the drug in liposomes or microemulsions which are compatible with body tissues. The
injectable formulations can be sterilized, for example, by
filtration through a bacterial-retaining filter or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water
or other sterile injectable media just prior to use. Suitable
inert carriers can include sugars such as lactose.
Suitable formulations include aqueous and non-aqueous
sterile injection solutions that can contain antioxidants,
buffers, bacteriostats, bactericidal antibiotics and solutes
that render the formulation isotonic with the bodily fluids of
the intended recipient; and aqueous and non-aqueous sterile
suspensions, which can include suspending agents and
thickening agents.
The compositions can take such forms as suspensions,
solutions or emulsions in oily or aqueous vehicles, and can
contain formulatory agents such as suspending, stabilizing
and/or dispersing agents. Alternatively, the active ingredient
can be in powder form for constitution with a suitable
vehicle, e.g., sterile pyrogen-free water, before use.
The formulations can be presented in unit-dose or multidose containers, for example sealed ampoules and vials, and
can be stored in a frozen or freeze-dried (lyophilized)
condition requiring only the addition of sterile liquid carrier
immediately prior to use.
For oral administration, the compositions can take the
form of, for example, tablets or capsules prepared by a
conventional technique with pharmaceutically acceptable
excipients such as binding agents (e.g., pregelatinized maize
starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose); fillers (e.g., lactose, microcrystalline cellulose or
calcium hydrogen phosphate); lubricants (e.g., magnesium
stearate, talc or silica); disintegrants (e.g., potato starch or
sodium starch glycolate); or wetting agents (e.g., sodium
lauryl sulphate). The tablets can be coated by methods
known in the art.
Liquid preparations for oral administration can take the
form of, for example, solutions, syrups or suspensions, or
they can be presented as a dry product for constitution with
water or other suitable vehicle before use. Such liquid
preparations can be prepared by conventional techniques
with pharmaceutically acceptable additives such as suspending agents (e.g., sorbitol syrup, cellulose derivatives or
hydrogenated edible fats); emulsifying agents (e.g. lecithin
or acacia); non-aqueous vehicles (e.g., almond oil, oily
esters, ethyl alcohol or fractionated vegetable oils); and
preservatives (e.g., methyl or propyl-p-hydroxybenzoates or
sorbic acid). The preparations can also contain buffer salts,
flavoring, coloring and sweetening agents as appropriate.
Preparations for oral administration can be suitably formulated to give controlled release of the active compound. For
buccal administration the compositions can take the form of
tablets or lozenges formulated in conventional manner.
The compositions can be formulated as eye drops. For
example, the pharmaceutically acceptable carrier may comprise saline solution or other substances used to formulate
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eye drop, optionally with other agents. Thus, eye drop
formulations permit for topical administration directly to the
eye of a subject.
The compositions can also be formulated as a preparation
for implantation or injection. Thus, for example, the compounds can be formulated with suitable polymeric or hydrophobic materials (e.g., as an emulsion in an acceptable oil)
or ion exchange resins, or as sparingly soluble derivatives
(e.g., as a sparingly soluble salt). The compounds can also
be formulated in rectal compositions, creams or lotions, or
transdermal patches.
The presently-disclosed subject matter further includes a
kit that can include an enzyme and/or a pharmaceutical
composition as described herein, packaged together with a
device useful for administration of the compound or composition. As will be recognized by those or ordinary skill in
the art, the appropriate administration-aiding device will
depend on the formulation of the compound or composition
that is selected and/or the desired administration site. For
example, if the formulation of the compound or composition
is appropriate for injection in a subject, the device could be
a syringe. For another example, if the desired administration
site is cell culture media, the device could be a sterile
pipette.
The presently-disclosed subject matter includes novel
small molecules. Also disclosed are small molecules that
inhibit Eis. Small molecule Eis inhibitors disclosed herein
aid in reducing KAN resistance and/or restoring KAN
susceptibility in Mycobacterium tuberculosis. The presently-disclosed subject matter further includes a pharmaceutical composition including a small molecule inhibitor, as
described herein, and a suitable pharmaceutical carrier,
optionally administered with Kanamycin. The presentlydisclosed subject matter further includes a method of treating tuberculosis, including aminoglycoside resistant tuberculosis, comprising administering to an individual an
effective amount of a small molecule Eis inhibitor, as
disclosed herein, to inhibit the Eis acetyltransferase of
Mycobacterium tuberculosis and reduce KAN resistance
and/or restore KAN susceptibility.
In certain embodiments, the present disclosure further
provides a method of treating, preventing and/or reducing
kanamycin resistance and/or restoring KAN susceptibility in
Mycobacterium tuberculosis. The method comprises at least
the step of administering an effective amount of a small
molecule inhibitor provided in the present disclosure to a
subject. In some embodiments, the subject is in need of
treatment. In some instances, the Mycobacterium tuberculosis strain is Mtb K204 or H37Rv. In some embodiments,
the small molecule is administered with an aminoglycoside,
for example, kanamycin. In some embodiments, the treatment reduces and/or eliminates the Eis-mediated KAN resistance of Mycobacterium tuberculosis.
Additionally, in certain embodiments, the inhibitors of the
present disclosure have a Mtb strain K204 MICKAN value of
less than about 5.0 µg/mL, of less than about 2.5 µg/mL, or
less than about 1.25 µg/mL. In other embodiments, the
inhibitors have a MICKAN value of less than about 0.625
µg/mL for Mycobacterium tuberculosis (Mtb) strain H37Rv.
The presently-disclosed subject matter is further illustrated by the following specific but non-limiting examples.
The following examples may include compilations of data
that are representative of data gathered at various times
during the course of development and experimentation
related to the present invention.

EXAMPLES
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This Example related to Eis inhibitors having the following scaffolds: the methyl 4H-furo[3,2-b ]pyrrole-5-carboxylate (scaffold 1) and the 3-(1,3-dioxolano )-2-indolinone
(scaffold 2) identified by high-throughput screening HTS,
the synthesis of 13 and 14 analogues of these scaffolds,
respectively, and their biochemical and biological testing.
First, we screened -123,000 small molecules for inhibition of KAN acetylation by Eis_Mtb. The HTS yielded two
promising scaffolds 1 and 2 (FIG. 1). Sixty compounds
containing scaffold 1 (FIG. 2) were present in the HTS
library. In these sixty compounds, the pyrrole ring was
decorated with different groups including alkyl chains, aryl
and oxazole rings, as well as amides. Fifty-nine of these
scaffold 1 molecules did not inhibit Eis_Mtb, however
compound la (FIG. 1, also labeled as 4kk in FIG. 2)
displayed some inhibition in the HTS. Because la contained
an aryl ketone group, we opted to synthesize la along with
12 additional analogues (1 b-lm) comprised of different aryl
groups (FIG. 1). For scaffold 2, ten compounds with different groups attached to the indolinone ring were in the HTS
library (FIG. 3). A hydrogen (Sa), an alkyl (Sb), an alkyl
ketone (Sc), a carboxylic acid (9a), or an amide (9b) substituent resulted in no Eis_Mtb inhibitory activity. Similarly
to the scaffold 1 analogues, aryl ketones of scaffold 2 (Sf-Sh)
displayed Eis_Mtb inhibition, with the exception of the
trifluoromethyl substituted aryl ketones (Sd and Se). Three
compounds synthesized from scaffold 2 (Sf-Sh, FIG. 3) were
found to be active. These and 11 of their analogues containing different aryl substituents for further study (Note:
Sf-Sh are numbered 2g-2i in FIG. 1 to represent the scaffold
2 series).
Compound la and 12 analogues (lb-lm) as well as 14
analogues for scaffold 2 (2a-2n) with different R substituents
were synthesized for structure-activity-relationship (SAR)
analysis of Eis_Mtb inhibition in vitro and in cellulo (FIG.
1). All new compounds were characterized by 1 H, 13 C NMR
(FIGS. S5-S56), mass spectrometry, and were established to
be ;;,;95% pure by HPLC prior to further testing.
TABLE 1

45

IC 50 values against purified Eis_Mtb and MIC values against
Mtb H37Rv and Mtb K204 witb tbe compounds at tbe
concentrations specified.

IC 50 (µM)"

Concentration
tested (µMl

H37Rv
MICKAN
(µg/mL)"

3 ± 1
2.9 ± 0.9
0.16 ± 0.07
0.25 ± 0.08
0.5 ± 0.2
>200
0.3 ± 0.1
0.6 ± 0.3
>200
5.8 ± 1.8
>200
>200
>200
0.33 ± 0.16
23 ± 10
0.30 ± 0.08
0.015 ± 0.005

100
100
15.5
25.1
52.6
100
33.9
64.5
100
100
100
100
100
32.6
100
29.7
1.5

,;1.25
,;1.25
,;1.25
,;1.25
,;1.25
,;1.25
,;1.25
,;1.25
,;1.25
,;1.25
,;1.25
,;1.25
,;1.25
,;1.25
,;1.25
,;1.25
,;1.25
,;1.25

50
Cpd

la
lb
55 le
ld
le
lf
lg
lh
li
60 lj
lk

11
lm
2a
2b
65 2c
2d

K204
MICKAN
(µg/mL/
a,)0,
5,
10,
10,
a,)0,
a,)0,
a,)0,
10,
10,
a,)0,
5,
10,
a,)0,
a,)0,
5,
10,
5,
a,)0,

10
10
10
10
10
10
10
10
a,)0
a,)0
10
10
10
10
5
10
2.5
10
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TABLE I-continued

while it displayed limited Eis inhibition in the HTS, which
could indicate that the compound in the HTS library was not
completely pure. We also found that the p-methyl derivative
2j displayed a 100-fold decrease in Eis inhibitory activity
(IC 50 =8.7±2.2 µM) from 2g and in combination with KAN
resulted in almost the same KAN MIC (5-10 µg/mL) against
KAN-resistant Mtb as 2g did. The non-substituted counterpart of parent 2g, derivative 2a, displayed weaker Eis
inhibitory activity (IC 50 =0.33±0.16 µM) and improved the
activity of KAN against Mtb K204 (MICKAN=5 µg/mL). We
also synthesized the m-fluoro, m-chloro, and m-bromo
derivatives 2c, 2d, and 2e. The m-chloro substituted 2d
showed the same inhibitory activity as that of 2g, but did not
sensitize Mtb K204 to KAN (MICKA?-10 µg/mL). The
m-fluoro and m-bromo substituted 2c and 2e resulted in a 3and 5-fold worse Eis inhibitory activity (IC 50 =0.30±0.08
and 0.54±0.25 µM), respectively. When used with the
m-bromo-substituted 2e, KAN had an MIC of 5-10 µg/mL
against Mtb K204. However, when used with the m-fluoro
substituted 2c, KAN displayed a better MIC value of 2.5-5
µg/mL. As observed with scaffold 1, the presence of
m-methoxy-phenyl, naphthyl, ethyl, and t-butyl groups in
scaffold 2 resulted in molecules that were completely inactive (IC 50 >200 µM and MICKA?-10 µg/mL against Mtb
K204). For scaffold 2, we also synthesized a m-nitro substituted compound (2n) to investigate the potential effect of
a strong electron-withdrawing group on Eis inhibitory activity. Compound 2n was less active (IC 50 =1.2±0.4 µM) than
2g, but it sensitized Mtb K204 to KAN (MICKAN=5-10
µg/mL). The absence of antibacterial activity of these compounds when used alone along with a general correlation
between IC 50 and MIC values indicated that inhibition of Eis
by these compounds is the main mechanism of sensitization
to KAN.
To investigate the selectivity of our inhibitors towards
Eis_Mtb, we tested two of our derivatives, one from each
series, le and 2c, against three other AAC enzymes with
different acetylation regiospecificities: AAC(2')-Ic from
Mtb, 5 AAC(3)-IV from E. coli, 12 and AAC( 6')-Ie/APH(2")Ia from Staphylococcus aureus. 13 Similarly to other known
non-Eis AACs, these three enzymes were previously shown
to be strictly regiospecific, but, like Eis, each enzyme was
capable of acetylating structurally distinctAGs. 40 Neither le
nor 2c inhibited KAN acetylation by these three AACs at
concentrations as high as 200 µM, which indicated that our
compounds were highly selective against Eis_Mtb.
To explain the results of our SAR study, we used previously published crystal structures of ternary Eis_Mtb-CoAcompound A (13g in ref14 ; PDB ID 5EC4) and B (llc in
ref14 ; PDB ID 5EBV) complexes to model our inhibitors la
and 2g in a position similar to that of inhibitors A and B
(FIG. 4). Without the crystal structures, de nova computational modeling of and screening for Eis inhibitors, including pharmacophore-based computer modeling, are invalidated by significant conformational changes in the Eis active
site upon inhibitor binding. 13 The inhibitors occupy the site
overlapping with the AG-binding site of Eis. The models
show that the cores of inhibitors la and 2g are surrounded
by the side chains of hydrophobic amino acid residues
(Trp36, the aliphatic part of Glu401, Ile28, Phe24, and
Val400). The cores stack with the indole ofTrp36, and in the
orthogonal direction they are sandwiched between Glu401,
the Eis C-terminus on one side and Ile28 on the other. The
acetophenone rings of both series 1 and 2 with different
substituents stack with Phe84, explaining why replacing
these aromatic rings with alkyl chains resulted in a loss of
activity for 11, lm, 21, and 2m. The acetophenone rings are

IC 50 values against purified Eis_Mtb and MIC values against
Mtb H37Rv and Mtb K204 witb tbe compounds at tbe
concentrations specified.
5

Cpd

ICso (µM)"

Concentration
tested (µM/

H37Rv
MICKAN
(µg/mL)"

2e
2f
2g
2h
2i
2j
2k
21
2m
2n

0.54 ± 0.25
>200
0.09 ± 0.03
2.2 ± 0.7
>200
8.7 ± 2.2
>200
>200
>200
1.2 ± 0.4

54.2
100
8.9
100
100
100
100
100
100
100

,;1.25
,;1.25
,;1.25
,;1.25
,;1.25
,;1.25
,;1.25
,;1.25
,;1.25
,;1.25

K204
MICKAN
(µg/mL/
10,
;,10,
5,
10,
;,10,
5,
10,
;,10,
;,10,
10,

5
10
5
5
10
10
10
10
10
5

10

15

aIC50 against purified Eis_Mtb enzyme,

bConcentrations of Eis inhibitor in the MIC assays. At these concentrations, these
compounds did not inhibit the growth ofMtb H37Rv or that ofMtb K204 when tested in
the absence of KAN. Concentrations of Eis inhibitors were l00x their IC 50 when IC50 <l 20
f?IM, or lQQf?IM for IC 50 >11 M.
cActivity of KAN against Mtb H37Rv.
dActivity of KAN against Mtb K204.
For c and d, results are from two experiments.

We evaluated biochemical (inhibition (IC 50 ) of purified
Eis_Mtb enzyme) and biological (effect on the KAN MIC
values for KAN-sensitive Mtb H37Rv and KAN-resistant
Mtb K204 cells) properties of these compounds, in parallel
(Table 1; FIG. 5). The freshly synthesized la, which displayed some inhibition of Eis_Mtb in the HTS campaign,
was confirmed to be a good Eis_Mtb inhibitor in vitro
(IC 50 =3±1 µM). In the presence of la, KAN displayed an
MIC of 5-10 µg/mL against Mtb K204. Having confirmed
the weak inhibitory activity of la, we explored the effect of
substitution on the phenyl ring on the aryl ketone part of
scaffold 1. Ortho substitution, as in 1b with a o-fluoro
substituent, resulted in almost the same Eis_Mtb inhibitory
activity (IC 50 =2.9±0.9 µM) as that for the parent la. KAN
MIC against Mtb K204 was unaffected by lb (MICKAN=l0
µg/mL). To establish if meta or para substitution would be
more favorable than ortho substitution, we generated compounds le-lj. For both meta and para substitutions, bulkier
substituents led to weaker Eis_Mtb inhibition (IC 50 >200 µM
for m-methoxy (lf) and p-bromo (li) compared to
IC 50 =0.16±0.07 and 0.3±0.1 µM for m-fluoro (le) and
p-fluoro (lg), respectively). Most of these derivatives (le-li)
did not improve KAN activity against Mtb K204. The
p-methyl derivative lj displayed almost the same Eis_Mtb
inhibitory activity (IC 50 =5.8±1.8 µM) and MIC value
against Mtb K204 as that of la. We generated lk (naphthyl
substituted) with the hope of strengthening any possible Jt-Jt
interaction between the inhibitor and the AG-binding site of
the Mtb Eis. This compound was found to be completely
inactive (IC 50 >200 µMand MICKAN=l0 µg/mL against Mtb
K204). Finally, replacing the phenyl ring with alkyl chains
(ethyl (11) and t-butyl (lm)) did not improve the Eis inhibition or MICKAN for K204 Mtb.
For scaffold 2, compound 2g-2i, which displayed Eis_Mtb
inhibition in the HTS, were freshly synthesized. The
p-fluoro substituted 2g displayed good Eis inhibitory activity (IC 50 =0.09±0.03 µM) and when used in combination
with KAN resulted in MICKAN of 5 µg/mL against K204
Mtb. The p-chloro substituted 2h was less active
(IC 50 =2.2±0.7 µM) than the p-fluoro substituted 2g and did
not sensitize Mtb K204 to KAN (MICKAN=5-10 g/mL). The
p-bromo substituted 2i was found to be completely inactive
(IC 50 >200 µMand MICKA?-10 µg/mL against Mtb K204),
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also surrounded by several hydrophobic amino acid residues
(Phe84, Trp36, Met65, Ala33). Therefore putting a polar
methoxy group in this hydrophobic environment would
likely destabilize Eis binding, explaining the IC 50 values of
>200 µM for if and 2f. The para position of the acetophenone
rings is flanked by Phe84 and Trp36, and it is -5 A away
from Trp13 and Met65, explaining why the bulkier bromo
substituents of li and 2i resulted in lower Eis inhibitory
activity, whereas the small fluoro substituents of 1 g and 2g
improved Eis inhibitory activity. The ortho position of the
acetophenone rings is flanked by Phe402, explaining why an
ortho substituent, as in 1b and 2b, resulted in a loss of Eis
inhibition. The models shows that there is space for small
substitution in the meta position of the acetophenone rings
(a -5 A-gap). Small substituents such as the fluoro and
chloro of le, ld, 2c and 2d fit well in the cavity, explaining
why these compounds displayed good Eis inhibition. However, bulkier substituents such as the bromo of le and 2e or
the nitro of 2n are too big to be accommodated at this site
and would clash with Eis residues, accounting for the poor
Eis inhibition by these compounds. We also determined that
the calculated Log P values of all compounds are in the
desirable range (0.98-3.75).
In sum, we have discovered two scaffolds with Eis
inhibitory activity. From 27 synthesized analogues of these
scaffolds with the variable acetophenone appendage, we
identified potent inhibitors of Eis. Growth inhibition studies
of our inhibitors in combination with KAN in KAN-susceptible Mtb H37Rv (MICKANsl .25 µg/mL) and KAN-resistant
Mtb K204 (MICKA?-10 µg/mL) showed that some of our
inhibitors were able to sensitize Mtb K204 to KAN. Smaller
substituents, like hydrogen and fluorine, yielded the best
compounds. In contrast, larger substituents, such as bromo
or methoxy dramatically decreased the potency of the compounds. The best compound identified was 2c with the
3-(1,3-dioxolano )-2-indolinone core and a m-fluoro-phenyl
substituent. This compound when used in combination with
KAN reduced the MICKAN for KAN-resistant Mtb to 2.5-5
µg/mL. While CLSI recommends MICKAN of 5 µg/mL on
Middlebrook 7H10 agar, it has no recommendation for
susceptibility testing by Alamar Blue, the method used here.
One study suggests a critical MICKAN of 2.5 µg/mL for
Alamar Blue testing. Since our inhibitors are able to return
KAN-resistant isolates to an MICKAN below the critical

concentration, essentially making resistant Mtb isolate
KAN-susceptible, such inhibitors could play a crucial role in
recovering KAN as a treatment option.
Example 2
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This Example related to Eis inhibitors having the scaffolds as set forth in FIG. 6 and reports report the chemical
synthesis of various compounds, along with their biochemical and biological studies. Among compounds in this series,
we have generated novel and promising Eis inhibitors that
not only efficiently inhibit the purified enzyme, but also
restore KAN sensitivity of KAN-resistant Mtb bacteria. We
also present a crystal structure of Eis in complex with CoA
and one potent inhibitor (compound 2k*), which explains
the structure-activity relationship (SAR).
Compound la* and 47 additional analogues la-3k with
different R 1 and R 2 substituents on the two phenyl rings and
either a fully aromatized (indicated by an asterisk after the
compound number) or a non-aromatized pyrrolo[l ,5-a]pyrazine core were generated for a thorough SAR analysis of Eis
inhibition (Scheme lB). The synthesis of all compounds
started with a reaction between the commercially available
pyrrole and 2-chloroethylamine, which afforded compound
4 in quantitative yield. Compound 4 was reacted with
different substituted benzoyl chlorides to obtain amides 5-7
in 66-71 % yields. The resulting amides were mixed with
phosphorus(V) oxychloride to generate cyclized products
8-10. Then, compounds 8-10 were reacted with various
substituted 2-bromoacetophenones
to obtain the desired non-aromatized products la-k, 2a-k,
and 3a,d,h,k. In order to generate the aromatized counterparts of these products, compounds 8 and 9 were first
aromatized in the presence of Pd/C to generate molecules 11
and 12. Conventionally, Pd/C is a hydrogenation catalyst. In
the absence of hydrogen gas, Pd/C is known to catalyze an
oxidative aromatization instead of hydrogenation. More
details about this heteroaromatic aromatization were summarized in an excellent review. 19 Compounds 11 and 12
were further reacted with the different substituted 2-bromoacetophenones to furnish the desired fully aromatized analogues la*-k* and 2a*-k*. These compounds were evaluated for Eis inhibition using the clinically relevant KAN as
the AG substrate (IC 50 values in Table 2).

TABLE 2
Inhibition of Eis-catalyzed KAN acetylation (IC 50 values) by tbe pyrrolo[l,5-a]pyrazine
derivatives as well as effect oftbese molecules on KAN MIC values for Mtb H37Rv and KANresistant Mtb K204.
H37Rv
Cpd#

R1

la
lb
le
ld

H
H
H
H

le

H

w

H

lg

H

lh
li
lj

H
H
H

R2
H
o-F
m-F
mCl
mBr
mOH
mOMe
p-F
p-Cl
p-Br

Aromatic

ICso
(µM)"

MICKAN
(µg/mLl

K204
MICKAN
(µg/mL)" Cpd#

d

d

Aromatic

H
o-F
m-F
mCl
mBr
mOH
mOMe
p-F
p-Cl
p-Br

no
no
no
no

0.47
1.4
0.7
0.15

0.05
0.4
± 0.2
± 0.04

,;1.25

>10, >10

no

0.07 ± 0.02

,;1.25

>10, >10

no

8.7 ± 1.6

d

d

no

1.3 ± 0.4

_d

_d

no
no
no

0.23 ± 0.02
0.5 ± 0.1
1.6 ± 0.5

,;1.25

0.2
0.2
± 0.01
± 0.1

_d

_d

2a
2be

,;1.25
,;1.25

10, 10
10, 10

2c
2d

p-F
p-F
p-F
p-F

no

0.44 ± 0.16

,;1.25

10, 10

2e

p-F

no

4.2 ± 1.7

2f"

p-F

no

0.15 ± 0.04

,;1.25

10, 10

2ge

p-F

no
no
no

0.039 ± 0.007
0.31 ± 0.09
0.76 ± 0.17

,;1.25
,;1.25

10, 10
5, 5

_d

_d

2h
2i
2j"

p-F
p-F
p-F

d

d

K204
MICKAN
(µg/mL)"

R2

0.9
0.7
0.05
0.5

±

H37Rv
MICKAN
(µg/mLl

R1

no
no
no
no

±

ICso
(µM)"
±
±

d

d

_d

_d

d

d

10, 5

d

d

_d

_d
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TABLE 2-continued

Inhibition of Eis-catalyzed KAN acetylation (IC 50 values) by the pyrrolo[l,5-a]pyrazine
derivatives as well as effect of these molecules on KAN MIC values for Mtb H37Rv and KANresistant Mtb K204.

Cpd#

R1

R2

Aromatic

lk

H

no

la*
lb*
le*
ld*

H
H
H
H

le*

H

lf*

H

lg*

H

lh*
li*
lj*
lk*

H
H
H
H

pMe
H
o-F
m-F
mCl
mBr
mOH
mOMe
p-F
p-Cl
p-Br
pMe

ICso
(µM)"
0.64 ± 0.18

H37Rv
MICKAN
(µg/mL/

K204
MICKAN
(µg/mL)" Cpd#

d

R1

R2

Aromatic

p-F

no

0.47 ± 0.08

5
5
5
5

2a*
2b*
2c*
2d*

p-F
p-F
p-F
p-F

pMe
H
o-F
m-F
mCl
mBr
mOH
mOMe
p-F
p-Cl
p-Br
pMe
H

yes
yes
yes
yes

0.35
0.29
0.22
0.06

±
±

0.07
0.07
± 0.05
± 0.02

,;1.25
,;1.25
,;1.25
,;1.25

yes

0.06 ± 0.02

,;1.25

5, 5

yes

8.4 ± 2.8

,;1.25

10, 10

yes

0.53 ± 0.11

,;1.25

5, 2.5

yes
yes
yes
yes

0.13
0.18
0.50
0.08

±
±
±

0.04
0.06
0.13
± 0.03

,;1.25
,;1.25
,;1.25
,;1.25

no

0.15 ± 0.05

,;1.25

10, 10

mCl
p-F

no

0.043 ± 0.006

,;1.25

>10, >10

no

0.11 ± 0.03

,;1.25

10, 10

pMe

no

0.11 ± 0.03

,;1.25

10, 10

yes

0.34 ± 0.10

,;1.25

2.5, 2.5

2e*

p-F

yes

1.8 ± 0.5

,;1.25

10, 5

2f*e

p-F

yes

0.21 ± 0.07

,;1.25

5, 5

2g*

p-F

2h*
2i*
2j*
2k*

p-F
p-F
p-F
p-F

3a

m,pdi-F
m,pdi-F
m,pdi-F
m,pdi-F

yes
yes
yes
yes

0.029
0.56
0.27
0.19

0.008
0.05
± 0.01
± 0.006

0.007
0.20
0.01
± 0.02
±
±
±

,;1.25
,;1.25
,;1.25
,;1.25

5,
5,
5,
5,

5,
1.25,
2.5,
2.5,

5
1.25
2.5
5

3d
3h
Control without an Eis
inhibitor:

1.25

K204
MICKAN
(µg/mL)"

2k

,;1.25
,;1.25
,;1.25
,;1.25

0.064
0.21
0.06
0.025

H37Rv
MICKAN
(µg/mL/

d

±
±

yes
yes
yes
yes

ICso
(µM)"

10

3k

d

d

5,
5,
2.5,
5,

1.25,
2.5,
5,
2.5,

5
2.5
2.5
5

1.25
5
2.5
5

aIC 50 values against purified Eis_Mtb enzyme.
bAnti-tubercular activity of KAN against Mtb H37Rv.
cAnti-tubercular activity of KAN against Mtb K204.
dThe inhibitor interacted with alamarBlue ® resulting in a color change, therefore, it was impossible to determine the MIC using this method.
ein MIC assays, the compounds were tested at concentrations that were 100-fold higher than IC50 . When the IC50 value was> 1 µM the compounds were tested at 100 µM. The compounds
were not toxic to Mtb in the absence of KAN at these concentrations.

We first tested whether the freshly synthesized parent
compound la* was indeed a potent Eis inhibitor. Expectedly, the freshly synthesized compound la* was found to
display potent inhibition of Eis (IC 50 =0.064±0.008 µM),
which was -6-fold better than the IC 50 value of the commercially available compound la* (IC 50 =0.36±0.03 µM)
from our previous HTS (Note: freshly synthesized powder
are often more active than HTS library compounds, which
may degrade upon storage). 18 The hit scaffold la* contains
a pyrrolo[l,5-a]pyrazine core, a phenyl ring adjacent to the
pyrrolo[l,5-a]pyrazine core (containing R 1 ), and an acetophenone moiety (containing R 2 ). A comparison of the
chemical structure of compound la* with those of the
previously published isothiazole S,S-dioxide-based Eis
inhibitors co-crystallized with Eis (FIG. 8) 15 suggested that
la* binds to Eis at the AG binding pocket20 similarly to the
isothiazole S,S-dioxides. Examination of the Eis crystal
structure bound to the AG tobramycin (TOB) (PDB: 4JD6 20 )
indicated that the positively-charged pyrrolo[l ,5-a]pyrazine
core is presumably essential for binding to the negativelycharged AG binding pocket and thus, should not be modified. Based on our previous survey of the hits of this HTS, 18
we also determined that the phenyl ring adjacent to the
pyrrolo[l,5-a]pyrazine core (containing R 1 ) is likely important for Eis inhibition. In fact, replacing the phenyl ring of
la* with an ethyl group resulted in a 25-fold reduction in the
inhibitory activity (IC 50 =9.25±1.50 µM). 18 Also from the
crystal structure of Eis in complex with the isothiazole
S,S-dioxide-based Eis inhibitors, we have rationalized that
this phenyl ring is important due to its snug fit in a
hydrophobic binding pocket in the AG binding cavity. On
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the other hand, the it-electron rich acetophenone moiety
(containing R 2 ) and the fully aromatic pyrrolo[l,5-a]pyrazine core were predicted to be crucial for binding due to
potential Jt-Jt interactions with aromatic residues within the
Eis binding pocket. However, it remains unexplored whether
and which substitutions at R 1 and R 2 positions would be
beneficial. We hypothesized that: (i) tailor fitting the Eis
binding pocket by introducing subtle modifications at R 1 and
R 2 would lead to the discovery of novel optimized inhibitors
from our hit scaffold la*, and (ii) disruption of the aromaticity of the pyrrolo[l,5-a]pyrazine core would be detrimental to the binding affinity of the molecule to the Eis binding
pocket. In our biochemical analysis, we will first examine
the aromatic compounds and then explore their non-aromatic counterparts. Both the aromatic and non-aromatic
molecules are divided into two series. In series 1, R 1 was
kept constant (R 1 =H), and various substituted acetophenones were installed onto the pyrrolo[l,5-a]pyrazine core
(changing R 2 ). Similarly, in series 2, R 1 was kept constant
(R 1 =p-F), and the same various substituted acetophenones
were installed onto the pyrrolo[l,5-a]pyrazine core (changing R 2 ). For the non-aromatic compounds, four additional
members were added to a third series (series 3) where R 1
was m,p-di-F.
We began our analysis of the aromatic compounds by
investigating series 1. To probe the ortho position of the
acetophenone moiety, compound lb* (R 1 =H, R 2 =o-F) was
generated and found to display a -3-fold reduction in Eis
inhibitory activity (IC 50 =0.21±0.05 µM) when compared to
the freshly synthesized parent la* (Note: from here on,
when comparing to la*, we refer to the freshly synthesized
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la*), indicating that ortho substitution was not beneficial.
We then explored substitutions at the meta position with
compounds le*-lg*. The meta-substituted compound le*
(R 1 =H, R 2 =m-F) was found to have comparable Eis inhibitory activity (IC 50 =0.06±0.01 µM) to the parent compound
la*. We systematically increased the size of the halogen
substituents in compounds ld* (R 1 =H, R 2 =m-Cl) and le*
(R 1 =H, R 2 =m-Br).
Interestingly, compound ld* displayed an IC 50 value of
0.025±0.006 µM, which was -3-fold smaller than that of the
parent compound la*. On the other hand, compound le*
(IC 50 =0.34±0.10 µM) was not as potent as compound ld*,
suggesting that the Br substituent was possibly too sterically
hindered and thus, not well tolerated in the Eis binding
pocket. Compound lf* (R 1 =H, R 2 =m-OH) (IC 50 =1.8±0.5
µM) was less potent than the parent compound, which
suggested that having a highly polar substituent could be
disfavored. Alternatively, replacing the hydroxyl group by a
methoxy (compound lg* (R 1 =H, R 2 =m-OMe)) yielded a
molecule with improved Eis inhibition (IC 50 =0.21±0.07
µM) when compared to lf*. Overall, we found that the Cl
was the best substituent at the meta position. We pondered
whether this trend would translate to the para position,
which prompted us to evaluate compounds lh* (R 1 =H,
R 2 =p-F), li* (R 1 =H, R 2 =p-Cl), and lj* (R 1 =H, R 2 =p-Br).
Intriguingly, the smaller F substituent was optimal at the
para position with an IC 50 value of0.029±0.007 µM contrary
to what we observed at the meta position.
Intriguingly, inhibitor lh* displayed an IC 50 of
0.029±0.007 µM, which, similarly to the IC 50 values for
several other inhibitors was smaller than the half of the
enzyme concentration used in our assay (0.25/2=0.125 µM).
This effect has at least three potential explanations: (1) If
inhibition of one monomer per Eis hexamer by one inhibitor
molecule leads to the loss of activity of the entire hexamer,
then the IC 50 can, in principle, be as low as 0.125/6=0.02
µM; (2) If only a fraction of Eis protein is active in
acetylating KAN and binding inhibitors (e.g., due to protein
aggregation), then the concentration of active Eis in the
assay is an overestimate of the concentration of active
enzyme; and (3) If inhibitor binding to Eis causes Eis
aggregation and inactivates multiple hexamers, then IC 50 is
also a fraction of the half of the enzyme concentration in the
assay. Mechanism #3 is unlikely, because we do not observe
global conformational changes in Eis upon inhibitor binding
in crystal structures. Distinguishing among these mechanisms of these highly potent analogues is a goal of ongoing
work in the group.
Subsequently, we investigated the effect of R 1 substitutions on the phenyl ring adjacent to the pyrrolo[l,5-a]
pyrazine core. As the p-F substitution was one of the best in
terms of activity when we varied R 2 in series 1, we first
decided to install the p-F substituent at the R 1 position and
generated series 2 analogues. Analogue 2a* (R 1 =p-F, R 2 =H)
displayed weaker Eis inhibition (IC 50 =0.35±0.07 µM) than
did la*. Similarly to 1b* (R 1 =H, R 2 =o-F), the ortho-substituted analogue 2b* (R 1 =p-F, R 2 =o-F) was also not optimal. When we increased the size of the R 2 substituents at the
meta position, we observed that the larger halogens led to
more potent Eis inhibition (Br=Cl>F) and yielded compounds with IC 50 values varying from 0.06 to 0.22 µM.
Unlike compound le* (R 1 =H, R 2 =m-Br; IC 50 =0.34±0.10
µM), them-Br substituted analogue 2e* (R 1 =p-F, R 2 =m-Br;
IC 50 =0.06±0.02 µM) was much more potent, which pointed
to the possibility that changing R 1 from H to p-F could lead
to a slight variation in the binding orientation of the molecule, especially near the meta position of the acetophenone

ring. Additionally, the m-hydroxy and m-methoxy substitutions, as in the cases of 2f* (R 1 =p-F, R 2 =m-OH) and 2g*
(R 1 =p-F, R 2 =m-OMe) either completely abolished Eis
inhibitory activity or resulted in moderate inhibition of the
enzyme (IC 50 =8.4±2.8 and 0.53±0.11 µM, respectively).
This was consistent with the observations made with compounds lf* (R 1 =H, R 2 =m-OH) and lg* (R 1 =H, R 2 =mOMe). For the para-substituted analogues (2h* (R 1 =p-F,
R 2 =p-F), 2i* (R 1 =p-F, R 2 =p-Cl) and 2j* (R 1 =p-F, R 2 =pBr)), similarly to what was observed with series 1, the larger
halogen substituents were generally less favorable with
activities varying in the range of 0.13-0.50 µM. We also
evaluated the para-methylated analogue 2k* (R 1 =p-F,
R 2 =Me) and found that 2k* displayed excellent activity with
an IC 50 value of0.08±0.03 µM, which was 2-fold better than
that of lk* (IC 50 =0.19±0.02 µM).
Having established the general SAR trends for the aromatic analogues, we next aimed to determine whether their
non-aromatic counterparts (la-k and 2a-k) would exhibit
decreased activity due to potential disruption of the itDit
interactions with Eis aromatic amino acid residues. Indeed,
we found that most of the non-aromatic analogues generally
displayed less potent Eis inhibition than their aromatic
counterparts did. In four out of 22 cases, the aromatic and
non-aromatic compounds display nearly equipotent inhibition of Eis. In the case of compounds le and le* (R 1 =H,
R 2 =m-F), the IC 50 values were virtually the same
(IC 50 =0.05±0.01 and 0.06±0.01 µM, respectively). Additionally, compounds 2e and 2e* (R 1 =p-F, R 2 =m-Br) were
also practically equipotent in terms of Eis inhibitory activities (IC 50 =0.07±0.02 and 0.06±0.02 µM, respectively).
Compounds
lg
and
lg*
(R 1 =H,
R 2 =m-OMe)
(IC 50 =0.15±0.04 and 0.21±0.07 µM, respectively) were also
similar. For the pair li and li* (R 1 =H, R2 =p-Cl)
(IC 50 =0.31±0.09 and 0.56±0.20 µM, respectively), the nonaromatic counterpart li was marginally better. Regardless of
whether the analogue in series 2 was aromatic or nonaromatic, it was conclusive that at the meta position of the
acetophenone moiety, bigger halogen substituents such as Cl
and Br were generally better suited, and at the para position
of the acetophenone, the smaller F substituent was the best.
Once our pyrrolo[l,5-a]pyrazine derivatives were optimized for inhibition of the purified Eis enzyme in vitro, we
set to confirm whether these compounds could display Eis
inhibitory activity in the Mtb culture, by measuring the
effect of the compounds on KAN MIC (MICKAN). Compounds were tested in combination with KAN against the
KAN-sensitive H37Rv Mtb strain as a control and against
the KAN-resistant Mtb K204, which is H37Rv Mtb bearing
a clinically occurring point mutation in the eis promoter
leading to overexpression of Eis. 4 Mtb H37Rv has an
MICKAN of 1.25 µg/mL, whereas KAN-resistant Mtb K204
has an MICKAN of 2:10 µg/mL. Active compounds were
expected to resensitize Mtb K204 to KAN. The compounds
were generally tested at concentrations that were 100-fold
higher than their respective IC 50 values in the enzymatic
assays, to correct for the variation in the potency of Eis
inhibition. Weakly potent compounds (IC 50 > 1 µM) were
tested at 100 µMin the MIC assays. Mtb is notorious for its
highly lipophilic and complex cell wall, which provides
intrinsic resistance to many antibacterial compounds and
presents an immense challenge for anti-tubercular drug
discovery. Indeed, as shown in our previous Eis inhibitors
studies, 15 some of the most potent in vitro compounds were
not active in Mtb cultures. We also cannot exclude low
solubility or aggregation of the compounds in the culture
media as a reason for poor activity. Herein, we determined
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the MIC values for KAN (MICKAN) against Mtb K204 in the
absence or presence of our Eis inhibitors and compared them
to the MICKAN of the drug-sensitive Mtb H37Rv strain. As
anticipated, most compounds caused a reduction in the
MICKAN for Mtb K204, overcoming KAN resistance. Poor
Eis inhibitors such as compounds 1fl' and 2:fl' with relatively
high IC 50 values were unable to resensitize Mtb K204 to the
action of KAN. These observations, together with the lack of
toxicity of these inhibitors when used without KAN for
either Mtb strains, validate Eis inhibition as the principal
mechanism of MICKAN reduction by these compounds. Mtb
H37Rv, for which MICKAN is virtually unaffected by the
inhibitors, serves as an important negative control in this
regard. Some of the good Eis inhibitors such as compounds
le-le, lg, lh, 2d, 2e, 2h, 3a, 3d, 3h, and 3k did not
resensitize Mtb K204 to the action of KAN despite their
nanomolarIC 50 values (MICKAN-"'10 µg/mL), indicating that
these molecules may not go through the cell envelope.
Compounds la*-le*, lg*, lh*, li, lj*, lk*, 2a*-2e*, 2g*,
2i*-2k* partially restored activity of KAN (MICKAN=2.5-5
µg/mL). Generally, the analogues in series 1 and 2 displayed
better potency compared to the analogues in series 3 in Mtb
culture. While the charged nature of these compounds may
contribute adversely to the permeability of the compounds
through the greasy mycobacterial cell envelope, their better
solubility in aqueous solution when compared to other
uncharged Eis inhibitors may offset this potential issue.
Therefore, these compounds serve as valuable alternatives to
uncharged Eis inhibitors of other scaffolds in further preclinical development of Eis inhibitors as KAN adjuvants in
TB therapy. Indeed, two compounds, li* and 2h*, are highly
promising for future development, as they completely
restore the potency of KAN, fully overcoming Eis upregulation.
Cytotoxicity to three different mammalian cell lines was
tested for five representative potent Eis inhibitors (FIG. 7) in
the absence and presence of KAN at the concentration of 50
µg/mL (equivalent to 86 µM) greatly exceeding the MICKAN
of Mtb. The negative control corresponded to no inhibitor
treatment and was standardized as 100% cell survival. The
positive control was a treatment with Triton 100-X®, where
we observed most of the cells killed. The cytotoxicity data
are presented in FIG. 7. We observed that at sub-IC 50
concentrations, our Eis inhibitors induced cell proliferation,
thereby displaying > 100% cell survival. With the exception
of compound le*, which at 50 µM exhibited significant
cytotoxicity against one of the three cell lines, none of the
compounds were cytotoxic against any of the three cell lines
up to 50 µM. Three compounds (li*, 2c*, 2h*) had no
significant cytotoxicity up to 100 µM, without or with KAN.
The lack of cytotoxicity indicates the absence of toxic
off-target effects in the mammalian cells, strengthening the
promise of these compounds as candidates for animal and
clinical studies. Eis inhibitors appear to be less toxic when
co-administering with KAN. Upon assessing the cytotoxicity of KAN alone (FIG. 9) and Eis inhibitors alone (FIG. 7),
one can observe that exposure to KAN or to Eis inhibitors
alone at sub-IC 50 concentrations promotes cell growth. This
phenomenon of increased growth in the presence of small
quantities ofxenobiotics has been previously observed. 21 - 25
Due to this effect, co-treatment with KAN and Eis inhibitors
may result in a faster cell growth than that for KAN alone.
To rationalize our SAR study and understand the binding
mode of our inhibitors to Eis, we determined a crystal
structure of Eis in complex with CoA and inhibitor 2k* (one
of our best inhibitors; IC 50 =0.08±0.03 µM) at the resolution
of 2.4 A (FIG. 10). The crystal structure demonstrates that

inhibitor 2k* is indeed bound in the AG binding site (established by our reported Eis-CoA-TOB crystal structure; 20
FIG. 8) and is stabilized in the bound state by numerous
hydrophobic interactions with Eis. The pyrazine ring is
stacked between the side chain of Glu401 of Eis and its
C-terminal carboxyl group, with mutually orthogonal Jt-Jt
interactions of the pyrazine ring with the indole ring of
Trp36. This observation supports our initial hypothesis that
the aromaticity of the pyrrolo[l,5-a]pyrazine core is crucial
for activity and explains why aromatized compounds
resulted in better activities during SAR analysis. Attached to
the pyrrolo[l,5-a]pyrazine core, the acetophenone ring displayed parallel Jt-Jt interaction with Phe84 and showed that
our prediction about the importance of the aromatic acetophenone was correct. Additionally, the R 2 -substituted acetophenone fits in a hydrophobic environment ofLeu63, Trp36,
andArg37. Hence, adding a polar hydroxyl group at R 2 , such
as in compounds lf, 1fl', 2f, and 2:fl', destabilizes binding
within the hydrophobic environment and results in weaker
Eis inhibitory activity. Furthermore, the para position of the
acetophenone ring is sterically restrained on all sides, being
sandwiched between Phe84 and Trp36 and abutting Trp13
and Met65, explaining why the larger groups in para position, such as in compounds li/i*, lj/j*, 2i/i*, and 2j/j*
resulted in decreased Eis inhibitory activities. This R 2 binding pocket of Eis accommodates structurally similar substitutions of our previously published inhibitors with different
core scaffolds (FIG. 8). Otherwise, these previously reported
inhibitors are bound in distinct orientations in the large AG
binding cavity. As shown in FIG. 10 and in our SAR
analysis, near the two meta positions of the acetophenone
ring, there are spacious pockets allowing incorporation of
larger substituents at the meta position without compromising activity. Lastly, the phenyl ring containing R 1 is located
in a spacious binding pocket lined by the terminus of the
phosphopantetheinyl tail of the CoA molecule, Asp26, the
C-terminal carboxyl group, Ser83, and Phe24, explaining
why a phenyl group is preferred over an ethyl group at the
R 1 position. In summary, the crystal structure of the
EisC204A-CoA-inhibitor 2k* complex allowed us to
explain our biological data and provides a basis for future
additional structure-based development of Eis inhibitors.
In conclusion, via a SAR study, we tailor-fitted Eis
inhibitors possessing the pyrrolo[l,5-a]pyrazine core to its
Eis binding pocket and identified multiple novel nanomolar
potency inhibitors. We validated our hypothesis that the
aromaticity of the pyrrolo[l,5-a]pyrazine core was important for activity and that aromatic analogues were overall
better inhibitors than their non-aromatic counterparts.
For the aromatic analogues, our study indicated that the
SAR strongly correlates with the size of the halogen substituent( s). At the meta position of the acetophenone, bigger
halogens such as Cl and Br were generally well tolerated. On
the other hand, at the para position, substitutions of a smaller
F atom and a methyl group produced analogues with substantially improved activities. The SAR analysis also
revealed that the substitution of a polar functional group
such as the hydroxyl group greatly perturbed the hydrophobic environment leading to decreased activity. These SAR
observations were explained by the crystal structure analysis, which will greatly facilitate future medicinal chemistry
studies. Most significantly, by in vitro Mtb culture assays,
we confirmed that our Eis inhibitors were capable of penetrating the Mtb cell wall and cancelling the KAN-resistance
ofMtb K204, which overexpresses Eis. As exemplified by a
clinically used combination of a ~-lactamase inhibitor, clavulanic acid, and penicillin, these Eis inhibitors may become
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similarly significant as adjuvant molecules in a combination
therapy with KAN to prevent emergence of and combat
KAN resistance in MDR- and XDR-TB.

synthesized by a reaction of 2,3-dihydroxyquinoxaline with
chlorosulfonic acid to generate sulfonyl chloride, which then
reacted with different aniline derivatives to yield compounds
29-47 (FIG. 12A).
Biochemical and Biological Testing of Sulfonamides
29-47.
To investigate the potential of these compounds as Eis
inhibitors for use in combination with KAN, we evaluated
their biochemical (IC 50 values against purified Eis enzyme)
and biological (effect on the MIC values of KAN in KANsensitive Mtb H37Rv and in KAN-resistant Mtb K204 2 )
properties in parallel studies (Table 3 and FIG. 15).

Example 3

5

This Example relates to the discovery and rational structure-based optimization via medicinal chemistry of promising sulfonamide Eis inhibitors that not only efficiently
inhibit the purified enzyme, but also restore KAN susceptibility of KAN-resistant Mtb. We also present a crystal
structure of Eis in complex with CoA and one potent

10

TABLE 3
IC 50 values against purified Eis and KAN MIC values against Mtb H37Rv and Mtb K204
in the absence and presence of the compounds at the specified concentrations.

Compound # Ar

29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

p-Br-Ph
p-Br-Ph
Ph
Ph
p-iPr-Ph
p-iPr-Ph
p-Cl-Ph
o-OMe-Ph
m-F-Ph
m-Br-Ph
m-OMe-Ph
3,5-di-OMe-Ph
m-Me-Ph
m-Et-Ph
m-iPr-Ph
m-nBu-Ph
m-tBu-Ph
2-naphthyl
4-OMe-2-naphthyl

X

Me
H
Me
H
Me
H
Me
Me
Me
Me
Me
Me
Me
Me
Me
Me
Me
Me
Me

IC 50

(~

M)"

0.08 ± 0.02
6.2 ± 1.3
5.8 ± 1.8
>200
0.25 ± 0.06
10.6 ± 2.5
0.100 ± 0.045
>200
3.0 ± 0.7
0.056 ± 0.004
5.8 ± 1.2
7.4 ± 3.3
0.37 ± 0.09
0.027 ± 0.012
0.23 ± 0.03
0.7 ± 0.3
27 ± 8
0.00024 ± 0.00010
0.30 ± 0.08

Concentration
tested (~M/

H37Rv MICKAN
(] g/mL)"

8
100
100
100
25
100
10
100
30
5.6
100
100
37
2.7
23
70
100
100
100

1.25
,;1.25
,;1.25
,;1.25
,;1.25
,;1.25
,;1.25
,;1.25
,;1.25
,;1.25
,;1.25
,;1.25
,;1.25
,;1.25
,;1.25
,;1.25
,;1.25
,;1.25
,;1.25
,;1.25

K204 MICKAN
(~g/mL/
10
2.5
5
5
10
2.5-5
5
2.5
10
5
2.5
,;1.25
5-10
2.5-5
5-10
2.5-5
5-10
5-10
,;1.25
10

aIC50 values and standard errors for inhibition of purified Eis enzyme,

bCompounds were tested at concentrations that were either 100-fold higher than their IC 50 or at 100 1 M if the IC 50 value could not be
achieved while keeping the DMSO concentration at sl % in test wells. At these concentrations, the compounds did not inhibit the growth
ofMtb H37Rv or that ofMtb K204 when tested in the absence of KAN.
cAnti-TB activity of KAN against Mtb H37Rv,
dAnti-TB activity of KAN against Mtb K204.

sulfonamide inhibitor, which reveals its mode of action,
explains our SAR study and paves the way for further
rational structure-based development of Eis inhibitors.
Identification and Chemical Synthesis of Eis Inhibitors.
To identify potential Eis inhibitor candidates, we used an
established UV absorbance-based HTS assay 12 to screen
over 123,000 structurally diverse small molecules for their
inhibition of KAN acetylation by the Eis_Mtb acetyltransferase in vitro. The screening of this molecular library
against Eis_Mtb led to the identification of a sulfonamide
scaffold (FIG. 12B). The HTS library contained 29 compounds (1-29) with this core structure, and four (1, 3, 4, and
29) were identified as hits (i.e., compounds displaying
;;,;3-fold higher inhibition than the magnitude of the standard
deviation). Compounds 2 and 5-28 were found not to inhibit
Eis in the HTS. As compounds 16-28 were unable to inhibit
Eis, we concluded that at least an aromatic ring attached to
the nitrogen atom is important for inhibitory activity. While
compounds 1, 3, and 4 displayed modest Eis inhibition,
compound 29 potently inhibited Eis activity (IC 50 =0.5±0.1
µM). Based on this encouraging result, we synthesized
compound 29 along with 18 additional sulfonamide analogues (30-47) containing a variety of substituents on the
aniline ring to define a preliminary body of structure-activity
relationship (SAR) of Eis inhibition. The compounds were
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Importantly, Mtb K204 is genetically identical to H37Rv,
except for one clinically derived point mutation in the eis
promoter that causes upregulation of Eis acetyltransferase
resulting in the resistance of Mtb K204 to KAN.2 In this
regard, H37Rv serves as an important Eis knockdown control for validating the mechanism of action of the Eis
inhibitors in the bacterial cell. To correct out the effect of
different potencies (IC 50 ) of the Eis inhibitors as determined
by the enzyme assay, in the MIC assays we used the
inhibitors at concentrations that were 100-fold higher than
their IC 50 values, where achievable. The freshly synthesized
compound 29 displayed robust inhibition of Eis in vitro
(IC 50 =0.08±0.02 µM). When combined with KAN, sulfonamide 29, resulted in a four-fold reduced KAN MIC value
(2.5 µg/mL) compared to KAN alone (10 µg/mL) for K204
Mtb. This was a reduction almost to the MIC level of KAN
in the KAN-susceptible Mtb H37Rv (1.25 µg/mL) parent
strain. To gain insight into the importance of the substitution
pattern on the aniline portion of the sulfonamide scaffold, we
generated secondary (NHAr) and tertiary (N(Me)Ar) sulfonamides (29-47). Eis inhibition assays with the synthesized
sulfonamides were carried out in combination with KAN.
The non-methylated counterpart oflead compound 29, compound 30, displayed lower Eis inhibitory activity
(IC 50 =6.24±1.31 µM) and had a smaller effect than 29 did on
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the KAN resistance in Mtb K204 (MICKAN=5 µg/mL). Two
other non-methylated derivatives, 32 and 34, also resulted in
lower Eis inhibitory activity (IC 50 >200 and 10.6±2.5 µM,
respectively) and did not overcome KAN resistance in Mtb
K204 (MICKAN=l0 and 5 µg/mL, respectively). These data,
in conjunction with the fact that compounds 1 and 3-13 from
the HTS did not display significant Eis inhibition, suggest
that the N-methyl group is essential for efficient Eis inhibition and antitubercular activity.
Having established the importance of the N-methyl moiety, we explored the effect of substitutions on the benzene
ring of the aniline moiety. Removing all substituents on the
benzene ring (compound 31) resulted in a 70-fold decrease
in Eis inhibitory activity (IC 50 =5.8±1.8 µM) when compared
to that of lead 29 and did not overcome KAN resistance in
Mtb K204, suggesting the importance of a substituted aniline for Eis inhibition and antitubercular activity. In general,
para substitution (compounds 29 with a p-Br, 33 with a
p-iPr, and 35 with a p-Cl) was found to be favorable and
yielded compounds with IC 50 values varying from 0.08-0.25
µM, which overcame KAN resistance (MICKAN=2.5 µg/mL)
in KAN-resistant Mtb. Interestingly, p-methoxy substitution
resulted in a compound (14) that was found to be inactive
during our HTS. To delineate if ortho or meta substitution
would be more favorable than para substitution, we generated compounds 36 (with an o-OMe) and 39 (with a
m-OMe). The o-methoxy substituted 36 was found to be
completely inactive (IC 50 >200 µMand MICKAN=l0 µg/mL
against Mtb K204), whereas the m-methoxy substituted 39
was found to be a potent Eis inhibitor (IC 50 =5.8±1.2 µM)
and was one of our two compounds to fully overcome KAN
resistance in Mtb K204 (MICKANsl.25 µg/mL). It is important to note that incorporating an additional m-methoxy
group, as in compound 40, was detrimental for the overall
activity of the molecule, which suggested that mono-substitution is more promising than di-substitution. We also synthesized the m-bromo derivative 38, which demonstrated a
slightly improved Eis inhibitory activity (IC 50 =0.056±0.004
µM) than did the corresponding para derivative 29, while
also being able to overcome KAN resistance in Mtb K204
(MIC=2.5 µg/mL). We also found that the m-iso-propyl
derivative 43 and its para counterpart 35 displayed similar
Eis inhibitory activity (IC 50 =0.23±0.03 and 0.25±0.06 µM,
respectively) and resulted in identical KAN MIC values
(2.5-5 µg/mL) against KAN-resistant Mtb. While the
p-methyl derivative 15 was inactive in our HTS, its meta
counterpart
41
displayed
good
Eis
inhibition
(IC 50 =0.37±0.09 µM) and some ability to overcome KAN
resistance in Mtb K204 (MIC 2.5-5 µg/mL). These data
suggest that mono-meta substitution is either equal or more
advantageous then para, which is more beneficial than ortho.
Based on these results, we generated additional m-alkylated
sulfonamides (42, 44, and 45) and observed that longer or
bulkier alkyl groups, although good for Eis inhibition, did
not produce compounds capable of overcoming KAN resistance in Mtb K204. Finally, with the hope of increasing any
possible Jt-Jt interaction between the inhibitor and the AGbinding site of the Mtb Eis, we generated compound 46,
which showed a dramatic increase in Eis inhibitory activity
(IC 50 =0.00024±0.00010 µM) and was found to completely
overcome KAN resistance in Mtb K204 (MICKANsl.25
µg/mL). Compound 46 is currently our most potent and
promising Eis inhibitor that can be used in conjunction with
KAN. Since compound 39 with the methoxy group in the
meta position is one of our best compounds to fully overcome KAN resistance in Mtb K204, we also synthesized
compound 47 with a m-methoxy substitution on the naph-

thy! group, but this led both to a loss of Eis inhibition and
to a loss of the effect on MICKAN (see next section).
The Eis inhibitors lacked anti-Mtb activity in the absence
of KAN in either tested strain (Table 3 ). Furthermore, most
compounds sensitized the KAN-resistant Mtb K204 to
KAN, as expected based on their 100-fold IC 50 concentrations used in these assays, with two compounds (39 and 46)
completely cancelling the effect of the Eis upregulation in
Mtb K204. The two compounds that were least potent in the
enzymatic assay (32 and 36) and used in the MIC assay at
concentrations below 100xIC 50 were also inert in that assay.
This general correlation of the potency in the enzymatic
assays and their effect on MICKAN canceling that of Eis
upregulation, taken together, validate inhibition of Eis by
these compounds as the mechanism of their sensitization of
Mtb K204 to KAN. Synergistic growth inhibition in combination with KAN by some effect other than Eis inhibition
can be ruled out because the inhibitors do not change
MICKAN in H37Rv. The cell envelope ofMtb is a notoriously
tough barrier, and some compounds penetrate the cell envelope more readily than others in a manner that is not
correlated with the IC 50 values. This would explain the
variability of MICKAN values in Table 3.
To examine the selectivity of our two best inhibitors (39
and 46) towards Eis, we next tested these two compounds
against three other AAC enzymes: AAC(2')-Ic from
Mtb, 19 • 20 AAC(3)-IV from E. coli, 21 • 22 and AAC(6')-Ie/
APH(2")-Ia from Staphylococcus aureus. 23 • 24 Sulfonamides
39 and 46 did not inhibit KAN acetylation by the AACs
tested at concentrations as high as 200 µM with the exception of 39, which inhibited 15% of the AAC(2')-Ic activity
when tested at 200 µM. These data demonstrate the high
selectivity of our inhibitors towards Eis.
Crystal Structure of EisC204A-CoA-Inhibitor 39 Complex.
In order to characterize the mechanism of our Eis inhibitors, explain the SAR, and aid in future drug development,
we determined the crystal structure of Eis in complex with
CoA and inhibitor 39 at the resolution of 2.1 A (FIG. 13 and
Table 4).
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TABLE 4
X-ray diffraction data collection and refinement statistics
for the EisC204A-CoA-inhibitor 39 ternary complex structure
(PDB ID 5IV0).

45

Data collection
Space group
Number of monomers per asymmetric unit
50 Unit cell dimensions

R32

a, b, c (A)
13, y ( 0 )
Resolution (A)
Ila
55 Completeness (%)
Redundancy

175.2, 175.2, 122.3
90, 90, 120
50.0-2.1 (2.14-2.10)"
16 (2.1)
95.8 (97.7)
3.9 (3.8)
0.08 (0.50)
37,907

a,

Rnerge

Number of unique reflections
Structure refinement statistics
60

Resolution (A)
R(%)
Rfree (%)
Bond length deviation (rmsd) from ideal (A)
Bond angle deviation (rmsd) from ideal ( 0 )
Ramachandran plot statisticsb

65 % of residues in most allowed regions
% of residues in additional allowed regions

40.0-2.1
19.4
21.9
0.006
1.35

93.8
6.2
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TABLE 4-continued

substituents in compound 47 led to a loss of activity, as both
substitutions cannot be sterically accommodated.
The overall conformation of Eis in complex with the
inhibitor is similar to the previously reported crystal structure. 5 A notable conformational difference is that a part of a
loop (residues 28-30) and a helix (residues 31-37) are shifted
towards the inhibitor relative to their conformation in the
structure without the inhibitor by 1-1.5 A, apparently in an
induced-fit fashion, to maximize steric contacts. The indole
ring ofTrp36 in this helix is rotated by -40°, maximizing the
stacking with the aniline ring and other interactions, as
explained above. These small, but significant conformational changes likely precluded us from obtaining a correct
model of a bound inhibitor by prior extensive computational
docking simulations. Inhibitor 39 occupies a similar space in
the AG binding pocket as a previously reported inhibitor
with the isothiazole S,S-dioxide heterocyclic core (labeled
13g in reference 17 ) (FIG. 14 FIG. 14), but the orientations of
the two inhibitors and their interactions with the protein side
chains are largely different. The only common feature is the
nearly coplanar binding of the methoxy- and the chlorophenyl rings of the two respective inhibitors, with both rings
sandwiched by Phe84 and Trp36 of Eis (FIG. 14 FIG. 14,
panel B). In summary, the crystal structure of the EisC204ACoA-inhibitor 39 complex allowed us to fully explain our
biochemical and biological data and provides a solid foundation for further rational structure-based development of
Eis inhibitors.
In conclusion, the biochemical, biological, and structural
studies described in this manuscript provide a proof-ofprinciple of the activity of Eis inhibitors as promising KAN
adjuvants. The SAR combined with the co-crystal structure
will guide future development of these compounds for their
clinical use against MDR- and XDR-TB.

X-ray diffraction data collection and refinement statistics
for the EisC204A-CoA-inhibitor 39 ternary complex structure
(PDB ID 5NO).

5
% of residues in generously allowed
regions
% of residues in disallowed regions

0.0
0.0 (0 residues)

"Numbers in parentheses indicate the values in the highest-resolution shell.
bindicates Procheck statistics. 29

Although sulfonamide 46 was our best compound in
biochemical and biological studies, it did not co-crystallize
with Eis. The crystal structure demonstrates that inhibitor 39
is bound in the part of the AG-binding pocket that is formed
by the N-terminal domain of Eis. The inhibitor binding site
partially overlaps with the binding site ofTOB, as observed
in our previously reported structure of Eis-CoA-TOB (FIG.
14), 7 indicating that the Eis inhibitors are competitive with
AGs. The inhibitor is apparently stabilized in the bound state
by numerous hydrophobic interactions (FIG. 13, panels B
and C). The shape of the inhibitor binding pocket and the
interacting hydrophobic residues are not conserved in other
AAC enzymes, explaining the observed selectivity of the
inhibitors. Specifically, the aniline moiety is stacked
between the rings of Phe84 and Trp36, with the methoxy
group located in the hydrophobic pocket lined by the nonpolar stem of the Arg37 side chain, Phe84, Trp13, and
Leu63. This explains why removing the aniline ring resulted
in a loss of activity for compounds 13, 16, 17, and 23-27.
The quinoxaline moiety stacks against Phe24, a residue that
also interacts with TOB (FIG. 14, panel B), as previously
observed in a crystal structure of an Eis-TOB complex (FIG.
14). 7 The NH group of the quinoxaline ring on the side of the
sulfonamide forms a hydrogen bond with the carboxyl group
of Asp26 (N---0 distance of 2.7 A) and the oxygen of the
sulfonamide forms a hydrogen bond with the main chain
nitrogen oflle28 (O-N distance of3.0 A). Our SAR studies
showed that compounds with an N-methyl group of the
sulfonamide moiety displayed higher Eis inhibitory activity
than those with an NH group, which can be rationalized by
the optimal van der Waals interaction of the methyl with
Trp36 (the distance between the methyl C atom and the
closest C of the Trp36 side chain is 3.6 A). Eliminating the
methyl group would abolish this interaction, putting a polar
NH in a hydrophobic environment, likely destabilizing
binding (6 vs 37, 30 vs 29, 32 vs 31, and 34 vs 33).
Replacing the aniline ring with an N-aryl piperazine (compounds 18-22) resulted in a loss of Eis inhibitory activity
when compared to the aniline ring. As described above, this
part of the molecule is snugly fit in a hydrophobic pocket,
which is too small to accommodate these larger groups. The
ortho position of the aniline ring is flanked by the C-terminal
residue Phe402 and it abuts Phe84, explaining why an ortho
substitution, as in compound 36, resulted in a loss of Eis
inhibitory activity. A bulky group such as n-butyl (44) or
t-butyl (45) in meta position of the aniline ring would clash
withArg37 that is structurally fixed by Jt-Jt stacking with the
inhibitor, explaining the poor inhibitory activity of these two
compounds. A meta,meta-disubstitution (40) resulted in a
dramatic decrease in activity as the second substituent would
clash with the side chain of Met65. Electron-donating
groups such as methoxy (39) or a naphthalene ring (46)
increase the Jt-Jt interaction of the aniline ring with Phe84
and Trp36, explaining their stronger interactions in the
AG-binding pocket of Eis. However combining the two
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This example relates to development of inhibitors of Eis,
which can be co-administered with KAN in order to prevent
inactivation by Eis in Mtb. Here, we report the identification
as well as the biochemical and biological characterization of
several potent inhibitors of Eis that were able to restore the
antibacterial activity of KAN in a KAN-resistant strain, Mtb
K204. To clarify in atomic details the mode of action of
these compounds and their structure-activity-relationships,
we also determined crystal structures of EisC204A in complex with CoA and two of these inhibitors.
High-throughput screening leads to the identification of a
promising Eis inhibitor scaffold. In order to identify Mtb Eis
inhibitors, we carried out a HTS of molecular libraries
comprising 123,000 structurally diverse small molecules
using a previously reported Eis acetylation assay in the
miniaturized format (FIG. la). 25 The initial HTS assay was
performed using the aminoglycoside neomycin B (NEO) as
a substrate, which was selected over KAN to maximize the
signal to noise ratio under the HTS conditions. However,
KAN was used in all post-HTS assays, since it is the
clinically relevant aminoglycoside. The HTS yielded 617
hits containing an isothiazole S,S-dioxide heterocyclic core
that were re-tested (FIG. 17). Of these 617 molecules, 133
showed reproducible inhibition of Eis enzymatic activity in
the same single-point HTS assay. Thirty-six of these 133
compounds were chosen for further testing in dose-response
assays, based on the potency of their inhibition of Eis in the
HTS assay and the structural diversity of their chemical
substituents (R 1 and R 2 groups). In a previous study of Eis
inhibitors evaluating fewer molecules, 25 we demonstrated
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that active compounds contained (i) a group that may
become positively charged, usually an amine, or (ii) an
aromatic group. The presence of either of these groups was
therefore also a criterion for selection of compounds for
dose-response testing. Additionally, we included four analogues that were not a part of the original library, but which
contained the same structural core (FIG. 16b). This process
yielded a group of forty molecules, for which we determined
IC 50 values against purified Eis. We also measured the effect
of these compounds on KAN MIC for KAN-susceptible
(H37Rv) and KAN-resistant (K204) Mtb strains (Table 5),
as described in the two following sections.

an aromatic ring, a branched alkyl group, a cyclohexyl
moiety, or a benzyl functionality did not efficiently inhibit
Mtb Eis. Among the forty compounds that were pursued
beyond the dose-response assay, compounds containing R 2
groups 8, 13, 15, 35, 46, and 81 inhibited Eis in vitro when
combined with multiple R 1 substituents, while other R 2
groups were shown to inhibit Eis in dose-response assays
when in combination with only one of the possible R 1
substituents (6b, 7b, Ile, 12e, 14c, 17i, 33a, 36d, 37b, 52i,
62i, and 112i). Overall, two large families ofR2 substituents
emerged as potential potent inhibitors of Eis: (i) compounds
with R 2 containing two nitrogen atoms separated by three
carbon atoms (structures 3, 6-8, 11-15, and 17), particularly
compounds with large bulky groups or a cyclohexyl ring
attached to the extended nitrogen atom were most often
inhibitory; and (ii) compounds containing an R 2 group with
two nitrogen atoms separated by two carbon atoms also
efficiently inhibited Eis (structures 33, 35-37, and 112). In
this series of molecules, only compounds with a nitrogen
atom located in a cyclohexyl ring were inhibitory.
We next explored the effect of the R 1 substituents on Eis
inhibition. Upon initial inspection of the 617 HTS hits, the
identity of the R 1 substituent appeared to have little effect on
their Eis inhibitory activity. However, when analyzing these
side chains statistically, patterns emerged. The p-fluorophenyl group (b) had the highest percentage (34%) of compounds inhibiting Eis in the initial HTS; this was followed
closely by the p-methylphenyl group (e, 33%) and the
m,p-dimethylphenyl group (i, 30%), suggesting that these
three groups as R 1 substitutions have a better chance of
contributing positively to Eis inhibition. The next best R 1
substituent was the p-chlorophenyl group (c) with 27% of
the compounds within this group displaying inhibition of
Eis. The m-chlorophenyl group (g) and p-anisole group (d)
were next with 19% and 18% of their compounds displaying
Eis inhibition, respectively. Finally, with 13%, 12%, and 9%
of compounds showing Eis inhibition were compounds
containing the p-isopropylphenyl (f), the m-bromophenyl
(h), and the phenyl (a) group as Ri, respectively.
Having established general trends for the R 1 and R 2
substituents, we next focused on the measured in vitro
potency (IC 50 ) of the forty selected compounds (Table 5).
Several trends consistent with those established above
emerged from these quantitative data. With the exception of
compound 112i, mono-substituted R 2 amine substituents
comprised of a straight alkyl chain (139b, 139e, 139i), an
aromatic ring (87b, 89b, 112b ), or an amide functionality
(115i, 116i) did not inhibit purified Eis. Compounds with R 2
substituents containing a diamine separated by two carbon
atoms with the second amine present in a cyclohexyl ring all
displayed good to moderate Eis inhibition. However, no
conclusion could be formed as to what type of cyclohexyl
ring was best, an unsubstituted (33a), a morpholino (35e, g,
h, and i), or a piperazinyl (36d or 37b) ring, as most IC 50
values were similar for these compounds. Compound 13i
with a diamine separated by three carbons at the R 2 position
and the m,p-dimethylphenyl group at the R 1 position was
found to be the most potent Eis inhibitor (IC 50 =0.054±0.002
µM). Interestingly, compound 46b with a cyclohexyl ring
directly attached to the core scaffold followed by a second
piperazine ring in the para-position was found to be the
second best Eis inhibitor (IC 50 =0.092±0.021 µM). These
results indicate that both a rotationally free alkyl chain (as in
compound 13i) or cyclically restricted alkyl linkers could be
useful in designing Mtb Eis inhibitors.
To establish whether the inhibitors identified were specific
to Eis over AACs from other families, compounds 46b and

TABLE 5

5

10

15

Eis inhibition IC 50 values of tested compounds and tbe
effect of tbe compounds on kanamycin A MIC values against
H37Rv and K204 Mtb strains.

Cpd

IC 50 (µM)"

Concentration
tested (µM/

3i
6b
7b
Sa
Se
llc
12e
13a
13e
13g
13i
14c
15e
15f
17i
33a
35e
35g
35h
35i
36d
37b
37d
46a
46b
46c
46h
52i
62i
81b
81g
87b
89b
112b
112i
115i
116i
139b
139e
139i

0.120 ± 0.035
0.152 ± 0.045
0.102 ± 0.034
2.85 ± 0.26
0.200 ± 0.036
0.238 ± 0.089
0.183 ± 0.043
2.82 ± 0.21
0.331 ± 0.071
0.234 ± 0.060
0.054 ± 0.002
0.112 ± 0.008
0.535 ± 0.045
0.148 ± 0.016
0.232 ± 0.038
0.123 ± 0.023
>200
2.49 ± 0.49
3.23 ± 0.99
0.985 ± 0.190
0.152 ± 0.031
0.657 ± 0.105
>200
0.432 ± 0.057
0.092 ± 0.021
0.109 ± 0.022
0.135 ± 0.031
0.580 ± 0.096
0.386 ± 0.080
1.25 ± 0.22
1.42 ± 0.42
>200
>200
>200
0.621 ± 0.229
>200
>200
>200
>200
>200

12
15.2
10.2
184.5
20
23.8
18.3
282.3
33.1
23.4
5.42
11.2
53.5
14.8
23.2
13.2
20
100
100
98.5
15.3
65.7
20
43.2
9.21
10.9
13.5
58
38.6
124.8
142.3
20
20
20
62.1
20
20
20
20
20

H37Rv
MICKAN
(µg/mL)"

K204 MICKAN
(µg/mLl

1.25
0.625
0.625
0.625
0.625-1.25
0.625
0.625
0.625
0.625
0.625
0.625
0.625
0.625
0.625-1.25
0.625-1.25
0.625-1.25
0.625
0.625
0.625
0.625
0.625
0.625
0.625
0.625-1.25
0.625-1.25
0.625-1.25
0.625
0.625
0.625
0.625
0.625
0.625
1.25
1.25
0.625
0.625
0.625
1.25
0.625
1.25
1.25

10
1.25
2.5
2.5
5
2.5-5
1.25
2.5
2.5
2.5
2.5-5
5
5
5
10
5
5
5
2.5
2.5
2.5
2.5-5
2.5-5
5-10
10
5
2.5
5
2.5
5
2.5-5
2.5
10
10
10
5
10
10
10
10
10
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aTbe IC50 values in the Eis acetyltransferase assay.
bAt these concentrations, these compounds did not inhibit the growth ofH37Rv or that of
K204 Mtb, when tested in the absence of KAN.
"KAN MIC values for H37Rv Mtb in the absence (first line) and in the presence of each
compound at the specified concentrations.
dSame as c, but for K204 Mtb.
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Structure-Activity Relationship Studies.
Various R 1 and R 2 side-chains in the identified isothiazole
S,S-dioxide heterocyclic scaffold (FIG. 16b, FIG. 17), were
explored to improve anti-Eis potency in vitro. Based on the
617 initial HTS hit molecules, we first drew several unambiguous conclusions about the desirable structure of the R 2
side-chain. Most of the compounds for which R 2 contained
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46c were tested against AAC(6')-Ie/APH(2")-Ia from
Staphylococcus aureus, 26 ' 27 AAC(3 )-IV from E. coli, 28 and
AAC(2')-Ic from Mtb. 29 ' 30 Under optimal reaction conditions for each enzyme, no inhibition by either compound
was observed with any of these AACs (Table 6). These data
demonstrate that the compounds are exquisitely selective for
Mtb Eis over other AACs.

Crystal Structures of Eis-Inhibitor Complexes Reveal the
Inhibition Mechanism.
To elucidate the mechanism of Eis inhibition by the
isothiazole S,S-dioxide heterocyclic core-containing compounds, rationalize the observed SAR, and guide future
rational inhibitor design, we determined 2.2 A-resolution
crystal structures of Eis in complex with CoA and inhibitors
13g and Ile (FIG. 18a,c), which displayed both potent
inhibition of Eis acetylation in vitro and the KAN resistance
abolishing effect in the Mtb cultures. Both inhibitors and
their chemical features were clearly distinguishable and
modeled into strong F -F c electron density (FIG. l8b,e). The
only exception was the 1,2,3,4-tetrahydroisoquinoline group
of l le, for which only partial electron density was observed
(FIG. 18e), likely due to a somewhat dynamic behavior of
this highly hydrophobic group in a partially polar environment, as allowed by the flexible diamine linkage. No other
significant difference electron density that could be attributed to a bound inhibitor was observed elsewhere. Both
inhibitors exhibited highsteric complementarity with the Eis
surface. The binding site for both inhibitors overlapped with
the aminoglycoside substrate-binding site, as was recently
established by the structure ofMtb Eis in complex with CoA
and tobramycin (FIG. 18cj; FIG. 20 FIG. 20 FIG. 20). 10 In
addition, the R 2 groups of both inhibitors reached the C-terminal carboxyl group of Eis, which was proposed to serve
as the general base in the acetyl transfer reaction. Therefore,
these crystal structures indicate that the inhibitors block
access of aminoglycosides to the active site of the enzyme.
Explaining the critical role of the isothiazole S,S-dioxide
heterocyclic core, this group is bound in the same location
and orientation in both Eis-inhibitor structures (FIG. 18).
Remarkably, despite the nearly identical positions of this
group, there are differences in how this group interacts with
the protein for the two inhibitors. These differences are due
to significant conformational changes in the region spanning
residues 26-31 of Eis (FIG. l8b,e), which uniquely adapts to
bind the two structurally different R2 groups. For inhibitor
13g (FIG. l8a,b,c), one of the sulfonyl oxygens forms a
direct hydrogen bond with the main chain amide nitrogen of
Phe84 and the ring nitrogen forms a water-mediated hydrogen bond with the main chain amide nitrogen oflle28. In this
case, the Eis conformation resembles that observed in a
previously reported crystal structure with the aminoglycoside-binding pocket unoccupied4 . Inhibitor Ile does not
make any water-mediated contacts due to a small positional
shift of the inhibitor and a conformational change of Eis.
Instead, the two sulfonyl oxygens are at a distance of -4 A,
consistent with the stabilizing van der Waals and electrostatic interactions. The isothiazole ring is sterically sandwiched between the side chains of Ile28 and Ser83 in one
direction and between the side chains of Phe24 and Trp36 in
the orthogonal direction. The R 1 groups of the two compounds are almost coplanar and fit neatly into a nearly fully
nonpolar environment of side chains Leu63, Trp13, and
Ala33, the aliphatic stem of Arg37, Met65, and Phe84,
explaining the nonpolar phenyl ring with small substitutions
as effective R 1 groups (FIG. 16). Such environment, devoid
of hydrogen bond donors or acceptors is appropriate for
accommodating halogen substituents, as is the case with 11 c
and 13g. The halogens can be accommodated in the para
and/or one, but not both meta positions. Substitutions at both
meta positions would not be accommodated, as reflected in
the list of potent inhibitors (FIG. 16), since one of them
would clash sterically with the side chain of Met65. In
contrast with R 1 , the conformations of the R 2 groups of the
two inhibitors are drastically different with one exception-

TABLE 6
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Inhibition of different non-Eis AACs by compounds
46b and 46c.

0

Compound

AAC

Concentrationa
(µM)

% activityb

200
200
200
200
200
200

100
100
80
100
100
75

15
46b
46b
46b
46c
46c
46c

AAC(2')-Ic
AAC(3)-IV
AAC(6')-lec
AAC(2')-Ic
AAC(3)-IV
AAC(6')-Ie

20

aMaximum inhibitor concentration tested.
bThe activity of the enzyme at the maximum inhibitor concentration (200 µM) relative to
that without inhibitor.
cThe acetylation activity of AAC(6')-Ie/APH(2")-Ia enzyme.

Eis Inhibitors Abolish Eis-Mediated Resistance of Mtb to
KAN.
Having identified inhibitors of purified Mtb Eis enzyme,
we next determined their activity in cellulo. Mycobacteria
are notorious for their waxy cell wall that is difficult to
penetrate for small molecules. Therefore, we anticipated that
not all of the compounds that exhibited inhibition of purified
Eis would be effective in cell cultures. We measured the
effect of the forty selected compounds (at a concentration of
100-fold higher than their IC 50 values) on KAN MIC values
against Mtb K204, a KAN-resistant strain bearing a clinically observed eis promoter mutation known to upregulate
Eis production (Table 5). In the KAN-susceptible H37Rv
strain, the MIC value of KAN is 1.25 µg/mL, whereas in the
KAN-resistant K204 strain, the MIC value of KAN is 10
µg/mL. As expected, compounds that did not inhibit purified
Mtb Eis (35e, 37d, 87b, 89b, 112b, 115i, 116i, and 139b, e,
and i) did not overcome resistance to KAN in Mtb K204. 28
of the remaining 30 Eis inhibitors resulted in at least a 2-fold
reduction in KAN MIC against Mtb K204, with two of these
compounds, 3i and Ile, lowering KAN MIC 8-fold, down to
the level of the KAN-susceptible H37Rv strain. Notably,
these compounds did not have any effect on growth of either
mycobacterial strain in the absence of KAN. Therefore,
these compounds act synergistically with KAN against
KAN-resistant Mtb. The compounds that reduced the MIC
value of the KAN-resistant Mtb strain 4-fold had IC 50 values
that ranged from 0.102±0.034 to 3.23±0.99 µM. Generally,
in vitro (Eis inhibition) and in cellulo (KAN-sensitization)
activities were correlated among the compounds tested in
both assays. This correlation, together with the lack of
inhibition of cell growth in the absence of KAN, serve as a
strong evidence for inhibition of KAN acetylation by Eis as
the principal mechanism of action in the mycobacterial cell.
Not unexpectedly, among very potent inhibitors of the
enzymatic activity of Eis in vitro, a small fraction of the
compounds had little or no effect at sensitizing the resistant
Mtb strain K204 to KAN. The lack of activity in the cells
was likely due to the inability of these compounds to go
through the cell envelope or due to their aggregation in the
cell culture media at the concentrations that were much
higher than those used in the enzymatic assay.
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the positively charged ring nitrogen of R 2 occupies nearly
the same location where it forms a salt bridge with the
carboxyl group of Glu401 in both structures. Besides this
interaction, R 2 group of compound 13g makes steric and
weak electrostatic interactions with His119, Ser121,
Glu401, and the C-terminal carboxyl group (weakly electrostatically interacting with the stem N) on one side and
making water-mediated steric interactions with region 26-31
on the other side. In contrast, for the R 2 of the compound
l lc: while the interactions with one face of this group are
made with the same amino acid residues, the other face
interacts directly through hydrophobic and steric interactions with the region 26-31, which is in a different conformation. Most prominently, the side chain of Asp26 is flipped
to interact with the stem, and Phe24 orthogonally stacks
against the double ring. Because the R 1 group abuts the
hydrophobic wall, whereas R 2 group points towards the
more extended end of the substrate binding channel, there is
more variability in both the identity and the size of R 2
substituents, as exhibited in the list of effective R 2 groups
(FIG. 17).

pool of compounds tested, we found agents that we validated
as potent inhibitors of Eis both in the test tube and in the
relevant Mtb cultures. Using a -5-fold larger and more
structurally diverse compound library than that used in our
initial effort 25 yielded compounds that were 10-fold and
more potent than those reported in that previous study.
Potencies in mid-nM range appear to be achieved through
binding of the compounds via steric complementarity,
hydrophobic and hydrogen bonding interactions. While one
substituent group (R 1 ) is relatively unchangeable in terms of
its size and physico-chemical properties, the other group
(R2 ) can greatly vary. The crystal structures of Eis-inhibitor
complexes demonstrate that binding to variable structures is
accompanied by conformational plasticity of the aminoglycoside-binding site of Eis, which adapts to different R 2
groups, while the protein-R 1 interactions are rigid body-like.
Binding of the two inhibitors of Eis investigated structurally
differs not only in protein conformation, but also in the
presence or absence of water-mediated contacts. Interestingly, the exquisite selectivity and potency of Gleevec
towards its target Ab! kinase have been recently elegantly
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TABLE 7
X-ray diffraction data collection and refinement statistics for the EisC204A-CoAinhibitor 11c and EisC204A-CoA-inhibitor 13g ternary complex structures.
11c

13g

175.2, 175.2, 122.3
90, 90, 120
50.0-2.2 (2.24-2.20)"
21 (2.9)
99.9 (100)
9.5 (9.4)
0.11 (0.62)
34,661

175.6, 175.6, 122.2
90, 90, 120
50.0-2.2 (2.24-2.20)"
24 (4.0)
99.8 (99.4)
7.3 (7.3)
0.10 (0.56)
34,541

Data collection
Space group
Number of monomers per asymmetric unit
Unit cell dimensions
a, b, c (A)
□,□,□(")

Resolution (A)
II□

Completeness (%)
Redundancy
Rmerge

Number of unique reflections
Structure refinement statistics

40.0-2.2
Resolution (A)
R(%)
19.4
21.5
Rfree (%)
Bond length deviation (rmsd) from ideal (A)
0.006
Bond angle deviation (rmsd) from ideal (
1.34
Ramachandran plot statisticsb
0

)

% of residues
% of residues
regions
% of residues
regions
% of residues

in most allowed regions
in additional allowed

40.0-2.2
20.0
23.8
0.007
1.46

94.1
5.9

93.2
6.8

in generously allowed

0.0

0.0

in disallowed regions

0.0 (0 residues)

0.0 (0 residues)

"Numbers in parentheses indicate the values in the highest-resolution shell.
bindicates Procheck statistics. 8

While it has been met with initial skepticism, target-based
rational drug design is now gaining momentum and is
widely used in industrial and academic drug discovery
pipelines, due to advances in HTS technology, robust assay
development practices and availability of large and diverse
chemical libraries. Prominent examples of successful rational drug design are HIV protease inhibitors ritonavir and the
anticancer drug Gleevec. Here, we report the discovery and
initial preclinical development of novel first-in-class isothiazole S,S-dioxide heterocyclic inhibitors of a unique acetyltransferase Eis from Mtb as an agent that overcomes one
mechanism of resistance to KAN in Mtb. Among the diverse
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shown to be a consequence of an induced-fit mechanism,
where Ab! undergoes unique conformational changes that
stabilize Gleevec in the binding site of this kinase and result
in a nM aflinity. 31 Our Eis inhibitors also appear to be
selective in that they do not inhibit other AAC enzymes. This
selectivity must be due to the structurally different substrate
binding pocket of Eis from that of regiospecific AAC
enzymes. Indeed, we demonstrated previously that even
though Mtb Eis shares main catalytic residues with Eis
homologues from different bacteria and even AAC(2')-Ic,
their substrate binding pocket topographies and the surface
charges differ dramatically. 12 For example, the C-terminal
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domain of Eis contributing to the shape of the substrate
binding pocket (and containing inhibitor interacting residue
Glu401 and the C-terminal carboxyl group) is absent in the
single-domain AAC(2')-Ic and other AAC enzymes. 4
Aminoglycosides are among the antibiotics of last resort
for MDR and XDR-TB patients, and resistance to them
strongly decreases the chances of a favorable treatment
outcome. The strategy of using KAN in combination with an
Eis inhibitor is meant not only to overcome KAN resistance
due to Eis upregulation, but also to curb emergence of new
resistant strains by mutagenesis of the eis promoter, as such
mutation would not have survival benefit in the face of
combination therapy. This study not only validates AAC' s as
drug targets, but has set an important precedent for HTSdriven discovery for AACs that cause resistance in clinically
useful non-TB pathogens, such as AAC(3) and AAC(6') in
Klebsiella pneumoniae. 32 - 34 As with TB, such inhibitory
agents could play an important role in both overcoming
existing resistance and curbing the acquisition of resistance.
We identified potent inhibitors of Eis enzymatic activity
with resulting sensitization of KAN-resistant Mtb cells, in
which the resistance to KAN is caused by Eis upregulation.
The inhibitors bind in the aminoglycoside binding pocket
blocking the access of aminoglycosides to the active site of
the enzyme. The inhibitor binding is accompanied by conformational changes of the protein. These compounds have
a great potential for further development as KAN adjuvants
in Mtb.
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This example relates to development of inhibitors of Eis.
The following compounds were prepared:
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Inhibition kinetics. IC50 values were determined on a
multimode SpectraMax MS plate reader using 96-well plates
(Thermo Fisher Scientific) by using the UV-Vis assay as
above taking measurements every 30 s for 20 min. Compounds were dissolved in Tris (50 mM, pH 8.0 adjusted at
rt containing 10% v/v DMSO) (100 l&L) and a 5-fold
dilution was performed. To the solution of inhibitors, a
mixture (50 l&L) ofEis (1 mM), NEO or KAN (400 l&M),
and Tris (50 mM, pH 8.0 adjusted at rt) was added and
incubated for 10 min, to allow for competitive binding.
Reactions were initiated by addition of a mixture (50 l&L)
containing AcCoA (2 mM), DTNB (2 mM), and Tris-HCl
(50 mM, pH 8.0 adjusted at rt). Initial rates (first 2-5 min of
reaction) were calculated, normalized and zeroed to appropriate controls. All assays were performed at least in triplicate. Data was fit to a Hill-plot fit using KaleidaGraph 4.1
software and IC 50 values were calculated, and results are set
forth in FIG. 21.
In order to assess the potential cytotoxicity of our inhibitors to mammalian cells, we selected our best Eis inhibitors
and tested their cytotoxicity alone or in the presence of KAN
againstA549, HEK-293, and J774A.1 cells. The percent cell
survival was summarized and presented in FIG. 22.
500 "'M (FIG. SX), we decided to perform the above
toxicity experiments with Eis inhibitors in the presence of
50 "'g/mL KAN (equivalent of 86 "'(M), which is 10-40x
MIC of KAN against Mtb H37Rv in order to better assess
the combined toxicity of Eis inhibitors and KAN (FIG. X).
Experiments were done in quadruplicate.
All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication,
patent, or patent application was specifically and individually indicated to be incorporated by reference, including the
references set forth in the following list:
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It will be understood that various details of the presently
disclosed subject matter can be changed without departing
from the scope of the subject matter disclosed herein.
Furthermore, the foregoing description is for the purpose of
illustration only, and not for the purpose of limitation.
What is claimed is:
1. A compound selected from the group consisting of:
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wherein R 1 is selected from the group consisting of H, p-F,
m,p-di-F; and R 2 is selected from the group consisting ofH,
o-F, m-F, m-Cl, m-Br, m-OH, m-OMe, p-F, p-Cl, p-Br, and
p-Me.
2. A pharmaceutical composition comprising the compound of claim 1, and a suitable pharmaceutical carrier.
3. A method of treating aminoglycoside-resistant Mycabacterium tuberculosis (Mtb ), comprising administering an
effective amount of the compound of claim 1.
4. The method of claim 3, and further comprising administering an aminoglycoside.
5. The method of claim 4, wherein the aminoglycoside is
kanamycin (KAN).
6. The method of claim 4, wherein the aminoglycoside is
administered to a subject in need of treatment for aminoglycoside-resistant Mtb.
7. A composition comprising the compound of claim 1
and an aminoglycoside.
8. The composition of claim 7, wherein the aminoglycoside is kanamycin (KAN).

* * * * *

